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Surgical excision of the primary tumor is an essential part of breast cancer treatment. 
While breast cancer prognosis has improved dramatically over the past decades, late 
relapses after apparently successful primary treatment are still an unresolved clinical 
issue. Locoregional recurrences can be challenging and there is no cure in the case of 
distant metastases. 
Purpose and aims 
The general aim of the project was to evaluate the influence of tissue trauma and 
wound healing on metastatic relapse of breast cancer.  
Methods 
Detailed studies of relapse patterns and dynamics in several retrospective breast 
cancer patients’ series were evaluated and related to surgical interventions as well as 
patients’ factors like body mass index and perioperative events. 
Results 
A relapse pattern with multiple metastases of similar size was discovered in 
subgroups of patients, suggestive of a growth synchronizing event on dormant 
micrometastases. A peak in early relapses after delayed reconstructions supported the 
hypothesis that tissue trauma and wound healing may stimulate pre-existing occult 
tumor deposits. The effect seems to be different if surgery involves the removal of a 
tumor in the breast or not. Patients factors and perioperative events can modulate this 
effect. 
Conclusions 
This work demonstrates that tissue trauma and wound healing can have an impact on 
distant relapse dynamics in breast cancer. The mechanisms of this link remain to be 
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ATRA  All-trans retinoic acid 
AZA   Azacitidine 
BCT   Breast conserving therapy 
BMI   Body mass index 
BMP   Bone morphogenic protein 
BRCA  Breast cancer associated gene 
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GFP   Green fluorescent protein 
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RECIST  Response evaluation criteria in solid tumors 
ROS   Reactive oxygen species 
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TGF   Transforming growth factor 
TNBC  Triple negative breast cancer 
uPAR  Urokinase type plasminogen activator receptor 
VEGF  Vascular endothelial growth factor 




Scientific environment ................................................................................................ 3 
Acknowledgements ..................................................................................................... 4 
Abstract ........................................................................................................................ 7 
List of Publications ..................................................................................................... 8 
Abbreviations………………………………………………………………………...9 
Contents ..................................................................................................................... 12 
1. Introduction ....................................................................................................... 15 
 1.1 Breast cancer……………………………………………………………...15 
  1.1.1. Epidemiology…………………………………………………...15 
  1.1.2 Diagnosis……………………………………………………………….15 
  1.1.3 TNM-classification and staging……………………………………..16 
 1.2 Treatment………………………………………………………...……….18 
  1.2.1 Surgery………………………………………………………………….19 
  1.2.2 Radiotherapy…………………………………………………..………19 
  1.2.3 Endocrine therapy…………………………………………………….20 
  1.2.4 Chemotherapy………………………………………………………….20 
  1.2.5 Targeted therapy………………………………………………………21 
  1.2.6 Immunotherapy………………………………………………………..22 
 1.3 Reconstruction……………………………………………………..……..22 
 13 
 1.4 Tumor biology and the hallmarks of cancer…………………….………..23 
 1.5 Tumor heterogeneity……………………………………………….…..…23 
 1.6 Relapse patterns…………………………………………………………..24 
 1.7 The metastatic process……………………………………………………26 
 1.8 Tumor dormancy………………………………………………………….27 
  1.8.1 Definitions and mechanisms…………………………………………27 
  1.8.2 Clinical evidence of dormancy ……………………………………...28 
  1.8.3 Biomarkers of dormancy………………………………………….….29 
 1.9 Wound healing and cancer as a wound…………………………………...30 
  1.9.1 The immediate response………………………………………………30 
  1.9.2 Inflammation…………………………………………………………...31 
  1.9.3 Proliferation, re-epithelialization and contraction……………….31 
  1.9.4 Resolution and remodeling…………………………………………..32 
          1.10 Tissue trauma and cancer………………………………………………..34 
 1.11 Perioperative interventions……………………………………………...35 
 1.12 Escape from dormancy………………………………………………….37 
 1.13 Targeting dormancy……………………………………………………..38 
2. Purpose and aims………………………………………………………………...40 
3 Materials and methods……………………………………………………………41 
3.1 Patients……………………………………………………………………41 
 14
3.2 Control group………………………………………..................................44 
3.3 In vivo model……………………………………………………………...44 
3.4 Statistical methods………………………………………………………...45 
3.5 Ethical considerations…………………………………………………….46 
3.6 Methodological considerations…………………………………………...47 
4 Summary of results…………………………………………………………….…49 
5. Discussion………………………………………………………………………...55 










1.1 Breast cancer 
1.1.1 Epidemiology 
Breast cancer is the most frequent malignancy in women, globally causing 24,2% of 
all cancer and 15% of all cancer death in women, making it the cancer form 
responsible for most female cancer deaths worldwide (1). Breast cancer in men is a 
rare disease, although with a worse prognosis, presumably caused by a different 
biology as well as lower awareness of the disease leading to later diagnosis (2).  
In Norway, median age at breast cancer diagnosis for women is 62 years, and the 
incidence is increasing. Some of this may be explained by improvement in diagnosis 
after introduction of mammography screening programs. However, the increase is 
also evident in women both below and above the age of inclusion in the screening 
program indicating other factors may be causing an actual increase in development of 
breast cancer. Risk factors include lifestyle aspects such as postmenopausal obesity 
(3), smoking (4), physical inactivity (5), low parity (6) and prolonged estrogen 
replacement therapy at menopause (7). Breast cancer survival has improved 
substantially over the past decades, reaching a 5-year relative survival rate of 90 %. 
Still, the risk of metastasis and breast cancer death remains after the 5-year time 
point, as demonstrated by a 15-year survival rate of 76 %. Manifest metastatic disease 
is considered incurable, and for stage IV disease, meaning distant metastases are 
present, 5-year survival is 29 %(8).  
 
1.1.2 Diagnosis 
Breast cancer is most commonly discovered by palpation of a lump in the breast or 
axilla or retraction of skin or nipple. Clinical findings suspicious of malignancy are 
evaluated with mammography and biopsy. Since the introduction of a mammography 
screening program and its expansion regarding age groups included, an increasing 
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proportion of breast cancer cases are detected before symptoms arise. The 
combination of increasing incidence and decreasing mortality has been attributed to 
earlier diagnosis, in combination with improved treatment. Criticism of this view has 
claimed that over half of screen detected breast cancers represent over-diagnosis of 
small tumors of unknown clinical importance (9). This has been refuted by others 
claiming there is a decline also in advanced breast cancer incidence. The Norwegian 
research council found in its evaluation of the mammography screening program a 
30% reduction in breast cancer related mortality among participants in the program 
(10). 
 
1.1.3 TNM-classification and staging 
Breast cancer stage is determined by tumor size (T), lymph node status (N) and 
presence or absence of distant metastases (M) as outlined in table 1, and informs on 
prognosis and choice of therapy (11). Breast cancers are categorized as primary 
operable or primary inoperable according to staging, see table 2 (12). For the primary 
inoperable cases, unless distant metastases are present, down staging may be 
attempted by neoadjuvant treatment with chemotherapy or endocrine therapy, the 
purpose being to reduce tumor size and thus shift the stage to an operable stage, and 








Table 1. TNM Classification, 8th Edition 
T0 No evidence of primary tumor 
T1 ≤2 cm (greatest dimension) 
T2 >2-5 cm 
T3 >5 cm 
T4 Involving chest wall/skin 
  
N0 No regional lymph node metastases 
N1 Movable axillary lymph node metastases 
N2 Fixated axillary lymph nodes or 
metastases to internal mammary nodes 
N3 Supra- or infraclavicular lymph node 
metastases or combination of internal 
mammary and axillary lymph node 
metastases 
  
M0 No distant metastases present 






Table 2. Operability according to stage level 
Primary operable  Primary inoperable 
Stage I T1N0M0 Stage II T3N0M0 
Stage II T0-2N1M0 Stage III T0-2N2M0 
 T2N0M0  T3N1-2M0 
   T4N0-2M0 
   T0-4N3M0 




Treatment modalities for breast cancer consist of local therapy: surgery and 
radiotherapy, and systemic therapy: endocrine therapy, chemotherapy and targeted 
therapy. Treatment decisions are guided by anatomical considerations such as tumor 
size and lymph node involvement, molecular markers like estrogen receptor (ER), 
progesterone receptor (PGR) and human epithelial growth factor receptor 2 (HER2), 
and lately also genetic alterations such as BRCA mutational status (13). Gene 
expression profiles have recently been demonstrated to distinguish subgroups of 
patients with a very low risk of relapse where chemotherapy can be safely omitted 
(14, 15). Increasingly tailored treatment, targeting aberrant pathways according to 
molecular markers is rapidly evolving, exploring the weaknesses of the particular 





Surgical removal of the primary tumor can roughly be divided into mastectomy, 
where the entire breast is removed, and breast conserving surgery, meaning excision 
of the tumor with an additional margin, with most of the breast left intact. Both breast 
conserving surgery and mastectomy is accompanied by sentinel node biopsy, 
meaning excision of the breasts first draining lymph node. If this lymph node 
contains a metastasis >2 mm in diameter, axillary lymph node dissection has been 
recommended to all patients. Current recommendations allow for omitting lymph 
node dissection if certain criteria are fulfilled, such as planned systemic adjuvant 
treatment, even in the presence of a positive sentinel node. This approach is 
demonstrated to not increase risk of relapse (16), and reflects the shift in role of a 
positive sentinel node from a locoregional problem, best managed by local 
interventions to a biomarker of disseminated disease (17). Norwegian national 
guidelines state that surgical, oncological and cosmetic circumstances should be 
taken into consideration when planning surgery for breast cancer, with oncological 
principles given highest priority. Breast conserving surgery is in general preferred, 
and when combined with postoperative radiotherapy the procedure has not 
demonstrated inferior outcome compared to mastectomy (18, 19). 
 
1.2.2 Radiotherapy 
The purpose of postoperative radiotherapy is to reduce the risk of a locoregional 
relapse, but has also been demonstrated to improve disease specific survival. Thus, it 
must also indirectly reduce distant recurrences (20). Radiotherapy is recommended 
for all patients after breast conserving surgery, large or locally advanced primary 
tumor, lymph node positive disease or where clear surgical margins were not 
achieved (12). Radiotherapy is administered after chemotherapy when this is 
indicated, otherwise after the postoperative period. 
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1.2.3 Endocrine therapy 
For estrogen receptor positive tumors, endocrine therapy can prevent systemic 
relapses when used in the adjuvant setting, and improve survival for patients with 
metastatic disease. Studies indicate clinical benefit when as little as 1% of tumor cells 
are positive for estrogen receptor, or 10% for progesterone receptor (21-23). Pre-
menopausal women are recommended treatment with a selective estrogen receptor 
modulator, tamoxifen, for five years, for high risk patients combined with ovarian 
suppression with goserelin, thereafter evaluating menopausal status. If the patient 
remains premenopausal, and is considered in a medium to high risk group, prolonged 
tamoxifen for another five years has been demonstrated to further reduce recurrences 
and mortality (24). This illustrates the persistent risk of late relapse for this group of 
patients. For postmenopausal women, the primary choice is an aromatase inhibitor for 
five years (12).  
 
1.2.4 Chemotherapy 
The rationale behind systemic adjuvant chemotherapy is the risk that the cancer may 
be systemic at the time of diagnosis. Cytotoxic drugs target dividing cells. As cancer 
cells in general are rapidly dividing, they are susceptible to such drugs, as can be 
deducted by the one-third breast cancer mortality reduction compared to no 
chemotherapy (25). The benefit of this reduction in relative risk depends on the 
absolute risk, without chemotherapy, which must be taken into consideration as all 
chemotherapy regimens come with adverse side effects. Short term side effects 
include nausea, hair loss and immunosuppression, increasing attention is also given to 
long term adverse effects like fatigue, cognitive impairment, neuropathy  and 
cardiovascular disease (26). As a consequence, more focus is given to de-escalating 
chemotherapy treatment as much as possible while maintaining oncologic outcome 
through better biomarkers and personalized treatment (27). The indication for 
adjuvant chemotherapy is determined by stage and expression status of hormonal- 
and HER2 receptors. For the low-risk patient group with ER+HER2-N0 status, it is 
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recommended to perform gene expression analyses to evaluate if chemotherapy can 
be safely omitted (27). When chemotherapy is indicated, it should in general include 
an anthracycline. In Norway, epirubicin, in combination with cyclophosphamide is 
given, for triple-negative and other high risk patients, followed by a taxane. 
Neoadjuvant chemotherapy may be used to reduce tumor size prior to surgery. Other 
advantages may be easier evaluation of treatment effect as the intact primary tumor 
may be evaluated for responsiveness. There has also been demonstrated a trend 
towards improved over all and disease free survival for preoperative compared to 
postoperative chemotherapy, possibly reflecting a benefit of early treatment of 
distant, undetected, micrometastases (28).  
 
1.2.5 Targeted therapy 
Targeted therapy is directed at defined molecular targets in the particular tumor of the 
individual patient. As such, endocrine therapy may be considered a form of targeted 
therapy as it is only given to patients with tumors expressing hormone receptors and 
these receptors are what the therapy targets. Still, by tradition, targeted therapy does 
not usually encompass endocrine therapy. An advantage of targeted therapies is that 
they, in general, come with milder side effects compared to chemotherapy. The first 
successful targeted therapy for breast cancer is usually ascribed to trastuzumab, a 
monoclonal antibody targeting HER2-receptors, preventing homodimerization and 
thus activation, with response demonstrated in the HER2 amplified subgroup of 
breast cancer (29). Introduction of cyclin dependent kinases (CDK)4/6-inhibitors is 
another example of successful targeted therapy for breast cancer. This group of 
compounds targets the transition from G1 to S-phase of the cell cycle, crucial for cell 
proliferation. In breast cancer, effect has been demonstrated in hormone receptor 
positive, HER2 negative metastatic disease in combination with endocrine therapy 





The dramatic responses to immunotherapy observed in tumor forms like melanoma 
and lung cancer (33) have, disappointingly, not been seen in breast cancer. So far, the 
small clinical benefit that has been reported is limited to the triple negative subtype, 
presumably because of a higher mutational load and elevated numbers of tumor 
infiltrating lymphocytes (34, 35). Trials further exploring a potential higher benefit 
by selection of patients, biomarkers, combinations with chemotherapy and timing of 
immunotherapy are ongoing (NCT03740893, NCT03395899, NCT03591276).  
 
1.3 Reconstruction 
The breast is an important part of the female body, regarding gender identity, self-
confidence and sexuality. The strong wish for breast reconstruction in a large 
proportion of breast cancer treated patients is well acknowledged (36). Surgery is the 
corner stone of breast cancer treatment, but concerns have been raised regarding the 
oncological safety of breast reconstructive surgery. This has been evaluated in several 
studies with diverging results (37-39). Reconstructive techniques available today 
include relatively small surgical procedures such as implant based reconstruction, to 
more extensive flap-based reconstructions and bilateral correction procedures. 
Immediate reconstruction should, according to Norwegian guidelines be considered 
for all patients where mastectomy is indicated (12). Delayed reconstruction, one year 
after adjuvant local and systemic treatment is completed and no evidence of 
metastatic disease has emerged, was previously considered most appropriate, and is 
still preferred for some patients.  Despite robust data demonstrating no survival 
benefit over breast conserving surgery (19, 40), mastectomy rates for early breast 
cancer are rising in the US (41). The reasons for this are not well understood but may 
be attributed to patients’ overestimation of risk of recurrence, not sufficiently 
reciprocated by treating physicians. While mastectomy rates in Norway are 
decreasing (42), the need for plastic surgery to restore appearance after breast cancer 
treatment remains, although in a different form. Oncoplastic techniques, meaning 
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usage of plastic surgery techniques during cancer surgery to maintain shape and to 
some extent volume of the breast, are increasingly used. As a rule of thumb, breast 
conserving surgery involving removal of more than 15% of the breast volume is not 
considered likely to result in an acceptable cosmetic result unless oncoplastic 
techniques are applied (43). 
 
1.4 Tumor biology and the hallmarks of cancer 
Cancer is characterized by loss of normal control mechanisms regulating proliferation 
and homeostasis, transforming a normal cell into a cancer cell. The complexity of 
these control systems is mirrored in the multifaceted alterations present in cancer. In 
2000, Hanahan and Weinberg published a review article describing a set of functional 
capabilities, or hallmarks, shared by most, if not all cancers, rationalizing this 
complexity (44). These were: self-sufficiency in growth signals, insensitivity to anti-
growth signals, evasion of apoptosis, limitless replicative potential, sustained 
angiogenesis and tissue invasion and metastasis. These capabilities are acquired by 
gain of function mutations in oncogenes and loss of function mutations in tumor 
suppressor genes, caused by insertions, deletions, genomic rearrangements, copy 
number alterations and epigenetic modifications. To these hallmarks two emerging 
hallmarks were later added: deregulating cellular energetics and avoiding immune 
destruction. Additionally, two enabling characteristics: 1) genome instability and 
mutation and 2) tumor promoting inflammation were included (45). This represents a 
move from an important, but reductionist focus of cancer as a disease of the genome, 
to an understanding of tumors as complex tissues with aberrations also in stroma and 
non-cancerous cells. 
 
1.5 Tumor heterogeneity 
Breast cancer is a heterogeneous group of malignancies with variable genetic 
characteristics resulting in different prognoses and responses to therapy. The classic 
 24
subgrouping according to hormone receptor status and HER2 amplification status 
guides treatment decisions as these markers are predictive of response to antiestrogen 
and anti-HER2 directed therapy respectively. They also inform of prognosis and 
relapse dynamics. The triple negative breast cancers, meaning cancer cells lacking 
expression of estrogen and progesterone receptors and not displaying HER2 
amplification, have the worst prognosis (46) whereas the estrogen receptor positive 
cancers have the most favorable outcome (47).  
The seminal publication on breast cancer subtyping based on gene expression profiles 
by Sørlie et al divided breast cancer into five distinct groups with different outcome, 
luminal A, luminal B, normal breast like, ERBB2+ and basal like (48). These groups 
somewhat, although not completely, overlap with traditional cell surface markers. 
The luminal A and B being ER positive and HER2 negative, the basal like being 
mainly triple negative and the ERBB2+ being HER2 enriched. The tumor 
microenvironment is also diverse in the different types of breast cancer. One example 
is the higher levels of immune cell infiltration in triple negative cancer, suggestive of 
a higher likelihood of effect of immunotherapy (49). While these are examples of 
inter-patient heterogeneity, meaning differences between patients, breast cancer also 
demonstrates intra-patient heterogeneity referring to differences between tumor 
manifestations within the same patient. Whole genome sequencing has demonstrated 
significant variation in alterations and mutations between the primary tumor and its 
metastases, with most metastases having acquired additional driver mutations not 
present in the primary tumor. This may be a result of both selective pressure from 
therapy and the immune system, as well as continued acquisition of mutations as an 
effect of deficient DNA-repair mechanisms (50). 
 
1.6 Relapse patterns 
The relapse patterns vary with breast cancer subgroup. The triple negative, basal like, 
tumors have the highest risk of relapse the first five years after primary treatment and 
the estrogen receptor positive ones, particularly the luminal A subgroup the lowest 
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(51). The risks, however, are time dependent, meaning that while the risk of relapse 
declines for the high-risk tumors after the first years, the risk is stable for a subgroup 
of the low risk tumors (52, 53), with relapses occurring as late as 25 years after 
apparently successful primary treatment. In addition to tumor characteristics, patient 
factors like overweight and obesity have been demonstrated to influence the relapse 
dynamics in breast cancer (54). A bimodal relapse pattern of breast cancer after 
primary therapy has been demonstrated in multiple patient series, with a first peak in 
relapses after roughly two years, and a second one at five to six years (Fig 1) (54-56).  
 
Fig. 1 First demonstration of the bimodal relapse pattern in breast cancer, from the 
Milan series, n=1173. Reprinted from (55) with permission. 
 
The first peak is, although not uncontroversially, explained by some to be elicited by 
a stimulating effect of primary tumor surgery, while the latter is considered to be the 
result of an accumulation of stochastic mutational events (57). Metastasis 
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organotropism is the tendency for a given cancer form to metastasize to certain 
organs. Breast cancer preferentially metastasizes to bone, liver, lungs and brain, with 
some variation between subtypes (58). While locoregional relapses may be diagnosed 
at routine follow up, distant metastases are usually detected when they cause 
symptoms, as follow up in Norway does not include imaging or blood sampling to 
detect biochemical alterations. It has repeatedly been demonstrated that physical 
examination and mammography are as effective as extensive follow up regimens 
regarding recurrence detection, overall survival and quality of life (59). As speed of 
metastatic development is heterogeneous, and patients vary in their proneness to seek 
medical advice when experiencing symptoms, distant metastases may have been 
present for a short or long time when diagnosed. 
 
1.7 The metastatic process 
Metastatic cancer is, with very few exceptions, incurable, and a majority of cancer-
associated deaths can be attributed to metastatic disease (60). Understanding the 
processes leading from localized to systemic cancer disease is therefore of utmost 
importance. In order to metastasize, cancer cells must undergo a series of events, all 
of which are, to a varying degree of success, attempted counteracted by the host (61).  
The first step in the metastatic cascade is detachment of cancer cells from the primary 
tumor and invasion into surrounding tissue matrix (62). This requires a 
reprogramming of the cells, from an epithelial state into a more mesenchymal, and 
thereby migratory phenotype. This process has been termed EMT, epithelial-to-
mesenchymal transition (63, 64) and will be expanded on in the subsequent section 
on wound healing. The invasive cells must then penetrate the blood or lymphatic 
vessel walls to intravasate to be transported to distant organ sites (65). In the blood 
stream, the cancer cells will encounter a range of host immune cells, which, 
depending on the degree of neoantigen expression and immune regulatory surface 
proteins on the cancer cell, may recognize it as foreign and elicit an immune response 
(66). In addition, the physical conditions with extensive shear stress must be 
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overcome (67). Other constituents of the intravasal environment may be beneficial to 
cancer cell survival. Platelets have been suggested to protect circulating tumor cells 
both by physically masking them with fibrinogen and by secreting factors such as 
transforming growth factor β (TGF-β) and platelet derived growth factor (PDGF) that 
inhibit anti-tumor immune activity (68).  
Upon arrival at a suitable metastatic niche, the cancer cell must extravasate and lodge 
in the pericapillary regions of the target organ. This process will most likely be very 
heterogeneous depending on the target organ, where bone marrow and liver with 
fenestrated capillaries, will permit passive diffusion of cancer cells. At the other end 
of the scale we find the blood-brain barrier needed to be penetrated in order to 
establish metastases in the central nervous system. After having succeeded with 
extravasation, the cells must undergo a mesenchymal-to-epithelial transition to regain 
proliferative traits needed to colonize the target organ (69). The metastatic process is 
documented to be highly ineffective, experimental evidence suggests that as few as 
0,02% of circulating tumor cells are able to form macrometastases despite the fact 
that the early steps are highly efficient (70). As early as in the 1880’s, Stephen Paget 
launched his “seed and soil”-theory, stating that in order for cancer to metastasize, the 
best suited cancer cell (seed) needs to find, and interact with, a receptive 
microenvironment (soil), this theory, to a large extent still holds forth today (71).  
 
1.8 Tumor dormancy 
1.8.1 Definitions and mechanisms 
Tumor dormancy, first described in 1954 (72), refers to a reversible state of little to 
no growth of cancer cells with maintained malignant potential and can be divided 
along several different axes. Primary tumor dormancy, where people harbor 
microscopic tumors without ever having been diagnosed with cancer, has been 
demonstrated in autopsy studies to be very frequent (73). Metastatic dormancy on the 
other hand is characterized by a latency to manifest metastatic disease after 
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apparently successful primary tumor treatment, thus resulting from early 
dissemination and a period of dormancy at the metastatic site. This has been ascribed 
to a maladaptation to the new microenvironment of the metastatic site, which may be 
quite different from the organ of origin, not permitting growth of the cancer cell until 
it has acquired new characteristics, better suited to this new milieu, or the 
microenvironment changes (74). Cancer treatment with chemotherapy can also 
induce dormancy, as has been demonstrated in vivo to be mediated by type I 
interferon (IFN) signaling. A clinical correlate in human was suggested by an 
association between serum IFN-β during neoadjuvant chemotherapy and longer time 
to recurrence (75). Withdrawal of hormonal stimulation can maintain cancer in the 
dormant state, as can be deducted from both the benefit of extended endocrine 
therapy, even after 5 years (24, 76), and by the synchronization of metastasis growth 
at ended adjuvant endocrine treatment, presented by us in this current work (77). In 
an ovariectomized immunocompromised mouse model, ER+ breast cancer 
micrometastases remained dormant until hormone therapy was initiated (78). 
The distinction can also be made between intrinsic dormancy, caused by genetic or 
epigenetic mechanisms within the cancer cell (79), and extrinsic dormancy, where 
micrometastases are kept dormant by immune control (80), angiogenesis restriction 
(81) or growth factor deprivation (82). Partly overlapping with the classification of 
intrinsic and extrinsic dormancy is the concept of cellular dormancy, cell cycle arrest 
in G0 phase of individual cells and population-based dormancy where there is a 
balance between proliferation and apoptosis (83). These classifications or variants of 
tumor dormancy are not mutually exclusive and can thus exist in the same patient at 
the same time.  
 
1.8.2 Clinical evidence of dormancy  
The fact that some cancer forms, breast cancer being perhaps the most widely 
recognized, can give rise to metastatic disease years or decades after primary 
treatment is considered indirect evidence of a period of dormancy as this cannot be 
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convincingly explained by other models of tumor growth (55). Evidence for immune 
mediated dormancy stems from the occurrence of donor derived cancer, where organ 
recipients, under immune suppressive treatment, develop cancer originating from 
donors considered cured from cancer, most frequently melanoma (84) but also other 
cancer forms, including breast (85). The cancer-immune system interaction is 
considered to span a scale of escape, equilibrium and elimination (86). Most cells 
undergoing malignant transformation are recognized and eliminated by the immune 
system. Some are able to escape the immune killing and cause clinical cancer. 
Micrometastatic dormancy is proposed to exist in a state of equilibrium with the 
immune system, where the micrometastatic deposit is prevented from expanding but 
able to survive.  
 
1.8.3 Biomarkers of dormancy 
A marker for the presence or absence of disseminated dormant cancer cells would be 
important information for follow-up of cancer patients. As of now, there is no 
clinically validated biomarker of dormant cancer. In breast cancer, the presence of 
disseminated tumor cells in the bone marrow after primary treatment is an 
independent prognostic marker (87), but we are not yet capable of distinguishing if 
these cells are truly dormant and harbor the potential of awakening. From basic 
science, the nuclear receptor NR2F1 displays potential as a marker of dormancy, and 
is currently being explored in clinical samples in breast cancer as well as other tumor 
forms (88, 89). Liquid biopsies are significantly easier and less invasive than bone 
marrow aspiration and have also demonstrated usefulness as a prognostic biomarker 
of late recurrence. In a series of ER positive, HER2 negative patients, without 
evidence of recurrence five years after primary treatment, detection of circulating 
tumor cells at five years was significantly associated with relapse (90). In a small 
group of late relapsing breast cancer patients, significantly differential expression of 
miRNA-21 and miRNA-200c was discovered in plasma at primary treatment 
compared to non-relapsing patients (91). TGF-β2 (92), bone morphogenic protein 
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(BMP) (93), growth arrest specific (GAS6) (94), retinoic acid, and IFN-β (75) are 
other systemic markers explored for potential clinical utility as biomarkers for tumor 
dormancy. 
 
1.9 Wound healing and cancer as a wound 
The process of wound healing is a carefully orchestrated series of events involving 
multiple local and systemic changes, all with the intent to restore tissue homeostasis, 
regain function and protect from infection. Whether the wound is caused by a 
traumatic event or deliberately inflicted by surgery, successful healing is crucial, as 
demonstrated by the major health issues caused by deficient wound healing capacity 
seen in diabetic patients amongst others. The analogy of cancer as “wounds that do 
not heal” was first presented by Harold Dvorak in 1986, mainly relating to the 
similarity of cancer stroma to granulation tissue (95). As described below, and 
previously reviewed by us (96), this metaphor holds true also when examining the 
wound healing phases and signaling today. 
 
1.9.1 The immediate response 
The first phase, initiated at tissue trauma, is blood clotting, if the injury involves 
blood vessels. The blood clot, predominantly consisting of cross-linked fibrin and 
platelets, previously considered merely a temporary physical sealing of the wound, is 
now known to have several biological functions such as release of growth factors 
from platelet granules and induction of vascular permeability by histamine and VEGF 
(97). VEGF also has immunosuppressive effects, potentially releasing cancer cells 
from immune restriction (98). Fig 2a. This, together with complement activation 
rapidly leads to the next phase, inflammation by chemoattraction of inflammatory 
cells. The cocktail of growth factors and other cytokines released by platelets upon 





First to arrive are the neutrophils, followed by macrophages and lymphocytes. 
Neutrophils secrete prostaglandin E2 (PGE2), and reactive oxygen species (ROS), 
further fueling inflammation with the purpose of eradicating invading bacteria (99). 
Macrophages also secrete PGE2 when stimulated by pro-inflammatory cytokines 
such as IL-6, and bacterial lipopolysaccharides (LPS)(100). PGE2 is prominent 
among the inflammatory mediators that also exert tumor-sustaining effects (101, 
102). Fig 2b. Among its functions in wound healing, that can also be utilized by 
cancer, are stimulation of proliferation, migration and angiogenesis, leading on to the 
next phase. 
 
1.9.3 Proliferation, re-epithelialization and contraction.  
Keratinocytes and fibroblasts from the wound margins are stimulated to migrate into 
the wound and proliferate, mainly by TGF-β which is secreted from activated 
platelets in the early phase and later by several cell types (103). In keratinocytes, this 
is preceded by a partial epithelial-to-mesenchymal-transition, EMT, whereby the 
keratinocytes downregulate cell-to-cell contact and hemidesmosomes, rearrange the 
cytoskeleton, extend lamellipodia and secrete proteases to be able to degrade 
connective tissue and move into the granulation tissue of the wound (104). Again, 
these mechanisms, when applied to cancer cells, facilitate invasion and dissemination 
and thus metastatic seeding. Fig 2c. In cancer, the EMT is more frequently complete, 
characterized by complete loss of cell-to-cell adhesions and expression of 
mesenchymal marker proteins like vimentin, resembling early embryogenesis, as 
opposed to the partial EMT in wound healing keratinocytes (64). In physiological 
wound healing, the keratinocytes, by an as of yet undetermined signal, reverts to the 
epithelial phenotype at completion of wound healing. For cancer cells to regain their 
proliferative potential, a mesenchymal-to-epithelial transition, MET, is also necessary 
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as the decision between EMT/MET state determines if the cell should “go or grow”. 
In wound healing, this MET takes place at the final phase, resolution and remodeling 
(103).  
 
1.9.4 Resolution and remodeling 
Resolution and remodeling is the least well understood and mapped phase of wound 
healing. Evidence of the importance of an ordered end of inflammation, proliferation 
and scar tissue deposition is seen both in chronic wounds and development of keloid 
scars where this final phase is hampered (105). Wnt signaling initiates epidermal 
development programs to re-stratify keratinocytes, this phase also includes regrowth 
of appendages (106), MMPs degrades and remodels the extracellular matrix to form 
organized collagen and proteoglycans, neutrophils and macrophages undergo 






Fig. 2 a) The immediate response. Activated platelets release growth factors that 
recruit inflammatory cells and stimulate vessel sprouting, re-epithelialization and 
degradation of matrix, but may also stimulate pre-existing dormant tumor cells at a 
distant site to proliferate and migrate. b) Inflammation. Neutrophils and macrophages 
secrete growth factors, cytokines, reactive oxygen species (ROS) and prostaglandin 
E2 (PGE2), fueling an inflammatory response in the wound and surrounding tissues. 
Systemic levels increase, and these factors are also known to be able to stimulate 
proliferation and migration of tumor cells. Systemic release of cortisol and adrenaline 
stimulates T-regulatory cells and can thus aid in cancer immune evasion. c) 
Proliferation, migration and contraction. Sprouting vessels produce tumor-promoting 
factors such as TGF-β. In order to re-epithelialize the wound surface, keratinocytes 
undergo a partial EMT. Fibroblasts generate scar-tissue and can aid cancer cells in 
invasion and migration. d) Resolution and remodeling. In normal tissue, 
inflammation and proliferation resolves by unknown mechanisms when tissue is 
regenerated, inflammatory cells return to the vasculature. A stiff, fibrotic 
environment can determine cytoskeletal reorganization inducing proliferation and 
metastasis formation in cancer cells located in this environment. Adapted from (96), 
with permission. 
 
1.10 Tissue trauma and cancer 
Surgical removal of the tumor was one of the first successful approaches to treat 
cancer, and to this day remains the cornerstone in curative treatment of many primary 
tumors. Breast cancer, however, is a clear example of the limitations of surgery. The 
repeated relapse of breast cancer, after successful removal of the primary tumor, led 
to increasingly aggressive surgical procedures. The most dramatic example being the 
mutilating ultra-radical mastectomies by Halstead in the late 1800s, based on the idea 
that relapse would be avoided by taking the tumor by its roots. Systematic follow-up 
of these patients demonstrated the futility of this practice as no improvement in 
distant relapse-free survival was detected after these very extensive surgeries (107). 
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The fact that the cancer could relapse, regardless of the extent of surgery, inspired the 
idea that dissemination to distant sites could be by the hematogenous route and thus 
independent of the anatomic limitations of the breast and associated lymph nodes. In 
an impressive effort to determine what physiological signaling could stimulate 
growth of metastases, the Fisher brothers, in the 1950’s and 60’s, performed a series 
of animal experiments testing a vast array of different interventions in rats implanted 
with a mammary carcinosarcoma. The stimuli ranged from anticoagulants and 
nutrition to the pituitary gland, thyroid and importantly, surgical trauma, which 
resulted in an increase in liver metastases after both laparotomy and liver resection 
(108, 109).  
When considering the events that must take place in order for a wound to heal, as 
outlined above, it is almost intuitive that cancer can benefit from the involved 
signaling: cells must proliferate and migrate, blood vessels must be made more 
permeable for cells to enter into and exit from the bloodstream. Add to that tumor 
fueling inflammation, an inevitable part of wound healing and the stage seems set for 
tumor growth and metastasis (45). Ample preclinical and clinical evidence of such an 
effect in many cancer forms has been published (110-113). It must be mentioned, 
however, that the exact opposite effect, namely inhibition of tumor growth by 
surgical trauma in adjacent tissue, has also been reported from animal models. In this 
study, the growth restrictive effect after repeated full skin excision was attributed to 
competition for growth factors (114). The survival benefit of surgically removing the 
primary tumor is undisputable and will remain an important part of cancer treatment 
in the foreseeable future. The systemic biological response to surgery, however, may 
be better understood and harnessed in order to minimize undesired cancer stimulating 
effects. 
 
1.11 Perioperative interventions 
As outlined above, the biology of tissue trauma and wound healing is complex and 
may have significant systemic effects. In addition, a range of systemic interventions 
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are made in the perioperative period to improve short term outcome and perioperative 
morbidity and mortality. This includes good hemostatic technique to reduce bleeding, 
prevention of infection and thromboembolism. To make large surgical procedures 
possible, anesthesia and analgesia are also necessary. Both the tissue trauma of 
surgery per se and the associated systemic interventions may have long term impact 
on oncologic outcome, and are attracting increasing attention (115, 116). Most reports 
on effects on oncologic outcome of perioperative interventions are based on 
retrospective analyses, thus the risk of a bias in selection of patients for the 
considered intervention is clearly present.  
From retrospective studies, intravenous anesthesia with propofol seems to improve 
oncologic outcome compared to inhalation anesthesia with sevoflurane, in breast 
cancer (117) and other cancer forms (118, 119). In a prospective randomized 
controlled trial of breast cancer surgery however, no statistically significant 
difference in 2-year relapse free survival was detected (120). A large, randomized 
study comparing short- and long-term survival between propofol and sevoflurane at 
primary surgery is currently recruiting patients with breast, colon or rectal cancer 
(NCT01975064).  
Treatment with NSAIDS (non-steroidal anti-inflammatory drugs) in the perioperative 
period has been suggested to have a beneficial effect on oncologic outcome. This has 
been supported by retrospective clinical data (121, 122) and pre-clinical studies (123, 
124), but again failed to demonstrate improved disease-free survival in a prospective 
trial of high risk breast cancer patients (125). 
The risk of thromboembolism is elevated both after surgery and the often 
accompanying immobilization and in cancer patients in general (126). 
Perioperatively, low molecular weight heparin is administered when the risk of 
thromboembolism is considered elevated, by patient factors such as obesity, 
cardiovascular comorbidity, smoking and active malignant disease, or surgery factors 
such as long duration of procedures. Epidemiological studies have suggested a 
survival benefit to cancer patients treated with low molecular weight heparin beyond 
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prevention of thrombosis, although results are inconsistent (127). Experimental 
systems have demonstrated anti-cancer properties of this class of drugs such as 
reduced sphere formation, migration, invasion, and angiogenesis (128, 129). A 
randomized controlled trial has demonstrated a survival benefit of a short course of 
low molecular weight heparin in patients with metastatic cancer, although no 
significant effect was seen in the breast cancer subgroup (130). 
 
1.12 Escape from dormancy 
Stimulated growth of cancer lesions after tissue trauma and wound healing has been 
demonstrated repeatedly, both in clinical and experimental settings (110, 112, 113). 
As mechanisms of dormancy are not yet fully understood, the evidence for how tissue 
trauma and wound healing can facilitate escape from dormancy is less clear.  
Coherent with the concepts of extrinsic and population-based dormancy is the theory 
of an angiogenic switch being capable of inducing escape from dormancy. This was 
first proposed by dr Judah Folkman in the 1970’s. According to his work, tumors of 
1-2 mm in size are restricted from further growth by lack of sufficient blood supply 
(131). At some time point, the hypoxia resulting from this hypoperfusion stimulates 
production of angiogenic factors such as VEGF, FGF, angiopoietins and others, 
causing blood vessels to sprout and supply the tumor with oxygen and nutrients to 
support further growth (132). This switch, from a non-angiogenic to angiogenic 
phenotype mediating escape from dormancy has been demonstrated in animal 
models, but as of yet lacks a convincing clinical correlate (133, 134). Another angle 
of the vascular-dormancy interaction is the proposal of the perivascular niche of 
stable vessel as dormancy inducing and maintaining via enrichment of 
thrombospondin-1, while tip cells of sprouting neovasculature produce periostin and 
TGF-β, promoting metastatic growth (135). 
The primary tumor is suggested to be capable of maintaining microscopic metastases 
in a dormant state, in models demonstrated to be mediated by production of 
 38
angiogenesis inhibitors (136) or immune modulation by IL-1β (137). Accordingly, 
removal of the primary tumor may have a dual stimulating effect on metastasis 
development, both through removing the tumor homeostatic restraint and stimulating 
growth by physiological wound healing signaling. 
Others have demonstrated escape from breast cancer dormancy in animal models 
mediated by inflammation (138), the key mechanisms suggested to be neutrophil 
extracellular traps (139), tumor associated macrophages (124), and neutrophils (138) 
respectively. The inflammatory stimuli in these studies has come from tobacco smoke 
(139), LPS injection (138) and surgical trauma (124, 140). In another publication, 
active inflammation was not necessary to induce escape from dormancy, but rather 
the fibrotic remodeling of the stroma after inflammation, by collagen-I enrichment 
(141). 
The intrinsic cellular machinery mediating the escape from dormancy has been 
demonstrated in vitro to be a shift in the balance of phosphorylation of ERK in 
relation to p38 induced by uPAR (142). Other models emphasize the role of 
EMT/MET in the transition from dormancy (138, 143). An in vivo model of breast 
cancer dormancy found an activation of the EMT program, mediated by transcription 
factor Zeb1 in previously dormant cells stimulated by LPS-injection (138). Adding to 
the complexity, mechanisms of escape from dormancy may be organ specific, in a 
mouse model of breast cancer, the TGF-β antagonist Coco reactivated dormant cancer 
cells in the lung, but not in other organs (74). 
 
1.13 Targeting dormancy 
With the mechanisms of dormancy maintenance and evasion still incompletely 
understood, how to best therapeutically target this problem is not determined. Non-
dividing, metabolically inactive cells are not considered susceptible to conventional 
cancer treatment (144). Still, there are a number of trials targeting residual disease in 
breast cancer with additional systemic therapy after standard of care adjuvant 
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treatment (NCT00248703, NCT03032406, NCT03400254, NCT01545648). In these 
studies, residual disease is defined by persistent tumor cells in the bone marrow after 
chemotherapy, and it may be argued that these cells were resistant to standard therapy 
rather than truly dormant.  
It has been proposed that one feasible approach to target dormant tumor cells would 
be to stimulate escape from dormancy, as the cells would, once awakened be 
susceptible to conventional cancer treatment such as chemotherapy and targeted 
therapy (145, 146). The argument against this is that since no cancer treatment today 
guarantees complete eradication of all malignant cells, one might risk inducing 
clinically manifest metastatic disease in a patient that without this attempt to treat 
never would have suffered from a relapse. Still, it has been attempted in a phase I trial 
in prostate cancer that was terminated due to low accrual. The strategy in this study 
was to mobilize dormant prostate cancer cells from the bone marrow to the blood 
stream by an anti-CXCR4 agent and then to target these cells with docetaxel 
(NCT02478125).  
Another suggestion is to develop therapeutics capable of maintaining dormancy. One 
phase II trial investigating the capacity of 5-AZA and ATRA to induce and maintain 
dormancy in prostate cancer treated patients with a biochemical relapse is currently 
recruiting patients (NCT03572387). This seems attractive, as dormant cells cause no 
problem to the host. However, experience from long term adjuvant treatment, such as 
endocrine treatment in breast cancer informs us that adherence to long term 
preventive treatment is low (147). It is difficult to motivate patients’ adherence to 
therapy over time, where they may experience side effects, but no immediate benefit, 
and where for a majority, the treatment makes no difference as they would never have 
had a relapse even without therapy. Perhaps the most feasible approach today, with 
our limited understanding of tumor dormancy mechanisms, would be short-term 




2. Purpose and aims 
General aim: 
The general aim of the project was to evaluate the influence of tissue trauma and 
wound healing on metastatic relapse of breast cancer. 
Specific aims: 
 To explore the relapse patterns in breast cancer patients presenting with first 
relapse for signs of synchronization of growth of metastases (paper I). 
 To evaluate relapse dynamics after delayed reconstruction in breast cancer 
treated patients (paper II) 
 To investigate the effect on recurrence dynamics after second surgery in breast 
cancer treated patients in different clinical and surgical situations (paper III).  
 To further examine the impact of events like complications, comorbidity and 
reoperations in the perioperative period for stimulating effects on relapse 












3. Materials and methods 
3.1 Patients 
Paper I is based on a retrospective series of 209 consecutive patients presenting with 
first relapse in breast cancer at Haukeland University Hospital between January 2005 
and December 2009. All diagnoses were verified and validated in the patients’ records. 
Time to recurrence was determined by time from primary surgery to occurrence of the 
first recorded distant metastasis. Exclusion criteria were: synchronous primaries and 
metastases, evidence of metastatic disease within 2 months after primary surgery, 
primary tumor not removed, local recurrences and patients with secondary, non-breast 
cancer. In addition, 12 patients had missing essential information. Thus, 180 patients 
remained for analysis of metastatic pattern, (Fig 3). Generally, a CT scan at time of 
first recorded metastasis was used to determine disease burden, but other radiologic 
modalities were also used. A single investigator (HD) measured all numbers and sizes 








Fig. 3 Inclusion and exclusion criteria paper I 
Paper II and IV are based on all mastectomy breast cancer patients who underwent 
delayed reconstructive surgery at Haukeland University Hospital, Bergen, Norway, 
after primary treatment for breast cancer between 1977 and 2007. After exclusions by 
Breast cancer relapse cohort n=209 
Excluded n=29 
   Metastases < 2 months after primary n=4 
   Intact primary tumor n=1 
   Local relapse n=8 
   Second, non-breast cancer n=4 
   Missing information n=12 
Study population n=180 
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criteria outlined in fig 4, the study group consisted of 312 patients. For paper IV, each 
patient’s record was studied to determine comorbidity, BMI, perioperative medication, 
reoperations and type and grade of complications according to CTCAE (Common 
Terminology Criteria for Adverse Events) version 4.0. Complications included in the 
analysis were: bleeding, systemic infection, local wound infection, mastitis, hematoma, 
seroma, necrosis, pulmonary embolus, pneumonia and flap dehiscence, all within 30 
days after surgery. Smoking status was categorized as current, previous or never 
smoker. Duration of surgery was extracted from the surgery planning software of our 









Fig. 4 Inclusion and exclusion criteria reconstruction study population and matched 
control group. 
Paper III is a comparison of the breast reconstruction patients’ series (REC) from 
paper II described above, and patients from three randomized clinical trials suffering 
from ipsilateral breast tumor recurrence (IBTR) (148) or contralateral breast cancer 
(CBC) (18, 149, 150) during follow-up. These studies were conducted to evaluate 
different surgical and radiotherapy approaches at primary tumor removal. Patient and 
tumor characteristics of these databases are shown in table 3.  
Breast reconstruction cohort n= 445 Control population from the Norwegian 
cancer registry n= 1341  
Matched control group  
(no reconstruction) n= 312.  
Study population. Reconstruction,  
n= 312 
Excluded n= 132 
 DCIS/LCIS n= 72 
 BCT n= 53 
 No cancer n= 1 
 Occurrence of other malignancies n= 4 
 Recurrence before reconstruction n= 3 
Missing information n=1 
Excluded n= 473 
 DCIS/LCIS n= 37 
 Reconstructed n= 179 
 BCT n= 196 
Missing information n= 61 




Table 3. Patient and tumor characteristics 
 IBTR (338) CBC 
(239) 
Rec (312) Controls (312) 
Median age at diagnosis 
(years) 
45 48 48 49 
25%-75% 39-52 42-56 42-53 43-53 
Range 21-69 22-75 29-73 28-71 
Tumor size (%) 
  T1 
  T2 
  T3/4 





















Node negative (%) 70 64 68 67 
Node positive (%) 30 36 32 33 
ER negative (%) 16 16 20 19 
ER positive (%) 63 53 70 70 





3.2 Control group 
The control group for paper II is based on a population from the Norwegian Cancer 
Registry comprising 1341 patients with breast cancer surgery in the same time period 
as our study population, that had not undergone reconstructive surgery. For data quality 
purposes, patient’s records were studied for validation of diagnosis, patient and tumor 
characteristics, adjuvant therapy, reconstructive surgery (excluded from the control 
group), time of first recurrence, and recurrent site in the same way as was done with 
the cases. Among the 1341 patients, a total of 473 patients were excluded leaving 868 
patients, whose characteristics are shown in Table 3, which hereafter will be labeled 
‘‘control group.’’ From this group, a one-to-one match with identical T- and N-stage, 
age at diagnosis and a recurrence free follow-up time equal to or greater than time from 
primary treatment to reconstruction for the matched case, was selected for each 
reconstructed patient. A reference day was created for each control, representing time 
from primary surgery to reconstruction for the matched case. 
3.3 In vivo model 
In an attempt to study the mechanisms of escape from dormancy stimulated by tissue 
trauma and wound healing, we turned to an in vivo model. We decided to use a murine 
tumor cell line as systemic effects of tissue trauma and wound healing could not be 
properly evaluated without an intact host immune system. We decided to use the Balb/c 
syngeneic mammary carcinoma line D2A1-d, described as retaining the ability to 
extravasate into lung parenchyma after intravenous injection, but failing to proliferate 
and form macrometastases in the absence of extrinsic stimulation (138). Cells were 
injected through the tail vein of female 8-week-old BALB/c mice to produce lung 
micrometastases, animals were subjected to mastectomy of the fourth mammary fat 
pad. In a second pilot study, we also labelled the cells with GFP, for easier detection 
of micrometastases and, more importantly, to induce an immune response described by 
others to result in an extrinsically imposed dormancy (124, 151). To be able to monitor 
tumor growth in real time, these animals were injected with cells both in the mammary 
fat pad and into the tail vein. None of these mice underwent surgery. In both pilot 
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studies, animals were sacrificed after 4-6 weeks and organs and tumors harvested for 
investigation. Formalin fixed, paraffin embedded lungs and orthotopic tumors were 
sectioned and stained with H&E and GFP (Invitrogen GFP Polyclonal antibody A-
6455, 1:5000).  
3.4 Statistical methods 
In paper I, standard deviation (SD) from size and number of metastases was calculated 
for each patient. The choice of SD as a marker of synchronization was based on the 
assumption that synchronized growth initiation would result in multiple metastases of 
similar size and thus result in a low SD, while unsynchronized, or random growth 
initiation would give few metastases of different size, resulting in a high SD. This is 
again based on the assumption that patients experiencing relapse undergo a period with 
resting occult micrometastases with restricted growth prior to their first relapse. These 
dormant micrometastases might be sensitive to systemic growth stimulating signaling, 
such as growth factors, cytokines etc., and thus, escape from dormancy, and start 
growing simultaneously.  
The median value of SD was used as cut-off value and patients, were grouped as ‘‘low 
SD’’ and ‘‘high SD’’, accordingly. Associations between different categorical 
variables were assessed by Pearson’s Chi-square test. Continuous variables not 
following the normal distribution were compared between two or more groups using 
the Mann–Whitney U tests. Univariate survival analyses were performed by the 
product-limit procedure (Kaplan–Meier method). Differences between categories were 
tested by the log-rank test. 
In paper II, event dynamics were studied by estimating with the life-table method the 
hazard rate for recurrence, i.e., the conditional probability of manifesting recurrence 
given that the patient is clinically free from any recurrence at the beginning of the time 
interval. The probability of recurrence over time, i.e., crude cumulative incidence 
(CCI), was estimated according to a proper nonparametric estimator adjusting for the 
presence of competing events and compared by the Gray test(152). A discretization of 
the time axis in six-month units was applied and a Kernel-like smoothing 
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procedure(153) was adopted. For multivariable regression analysis, the piecewise 
exponential model was used. The piecewise exponential model provides a flexible 
semiparametric tool in the study of the hazard function for survival data, in the same 
fashion as a Cox regression model (154). The log-hazard function was modeled as an 
additive function of the baseline log-hazard and the covariate effects. Statistical 
analyses were done using R3.02 software for Windows with Epi package added. 
In paper III, distant metastasis free survival times were calculated as time from second 
surgery (IBTR, CBC or REC respectively) to metastatic relapse or last documented 
follow-up with no evidence of disease. Relapse dynamics were analyzed with t=0 at 
the time of second surgery, separate analyses were performed investigating the 
influence of time from first to second surgery, grouped in 12-month intervals. Second 
primary tumors, including new contralateral breast cancer, were considered competing 
events leading to censoring at the time of occurrence. The distant metastasis dynamics 
was studied by estimating with the life-table method the hazard rate for recurrence, i.e., 
the conditional probability of manifesting recurrence given that the patient is clinically 
free from any recurrence at the beginning of the interval. 
In paper IV, relapse dynamics were evaluated by using the life-table method for the 
hazard rate of recurrence, as in paper II. Curve smoothing was done with natural 
splines, polynomial inverse third order. Differences between groups were analyzed 
with the Mann-Whitney U-test for continuous variables and X 2-test for categorical 
variables. 
3.5 Ethical considerations 
Ethical approval for the studies was granted by the Regional Ethical Committee (REK 
Vest): 15025. All animal experiments were conducted in accordance with the 
regulations of the Norwegian state commission for laboratory animals, which are 
consistent with the European convention for the protection of vertebrate animals used 
for experimental and other scientific purposes and Council of Europe (ETS 123) and 
approved by the Norwegian Food Safety Authority, FOTS ID 12083, and the Animal 
care and use program at the University of Bergen. 
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3.6 Methodological considerations 
The use of standard deviation of metastases as a marker of synchronized growth (Paper 
I) is novel and thus needs to be confirmed in different data sets. There is also a 
possibility that size dependency of SD makes direct comparison between very small 
and very large metastatic lesions inaccurate. The choice of the median SD as a cut off 
value between synchronized and non-synchronized was chosen due to a lack of 
previous data or biological rationale for another value, and to avoid strong influence of 
extreme values.  
 
The fact that breast cancer follow-up in Norway only includes imaging upon symptoms 
or other reasons to suspect distant metastases such as biochemical alterations, 
introduces uncertainty regarding duration and growth rate of metastases. This may have 
diluted the observed effect. Expanding the studies to multiple centers would have 
augmented sample sizes and made statistical significant results more robust and 
reliable. It would also, however, introduce a risk of inter-observer variability in 
measurements of metastatic lesions on radiological images and other variables 
dependent on some level of observer interpretation. No statistical tests were used to 
predetermine sample size in any of the studies, as the direction and magnitude of effects 
were unknown. The reliability of subgroup analyses of different reconstructive 
methods regarding relapse dynamics is also limited due to small number of patients 
and few events in this group.  
 
Retrospective studies of patients’ groups call for careful consideration of selection 
criteria. A risk of selection bias in paper II could be an accumulation of early relapses 
in the no reconstruction control group, as any sign of metastatic disease is a 
contraindication for delayed breast reconstruction. This was accounted for in the 
present study by only including controls with a follow up free from relapse at least as 
long as time from primary surgery to reconstruction for the matched case.  
 
The piecewise exponential model used in paper II was proposed by Iacobelli et al (155), 
and although not as common as the widely used Cox proportional hazard model, it has 
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several advantages in the current analyses. It does not assume proportional hazards, 
that is the idea that the covariates will have a proportional effect that is constant over 
time, making it better suited to study disease dynamics over time. Other survival 
models generally assume that an intermediate event, in our case the breast 
reconstruction, only has a constant, multiplicative effect on the baseline hazard after 
its occurrence. Such an assumption may lead to a clinically relevant bias as the 
intermediate event may act not only by multiplying the baseline risk, but also changing 
the following dynamics. In our work, to allow for non-proportional hazard in 
estimating the effect of event occurrence, time elapsed from the event occurrence to 
the end point of interest, namely the new time scale induced, was also accounted for in 
the model. Thus, we included both the event itself, breast reconstruction, follow-up 
time from the event and time since primary tumor removal in the multiple timescale 
model. Time since event occurrence was set to 0, before its occurrence as well as for 



















4. Summary of results 
Paper I was the first published systematic evaluation of metastatic pattern regarding 
sizes and numbers in breast cancer patients. Bone- (38 %), lung- (30 %) and liver 
metastases (23 %) were the most frequent metastatic sites. The median number of 
lesions measured was 7 (mean 6). We proposed the standard deviation (SD) of size 
and number of metastases as a marker of synchronized growth. Median SD in the 
population was 5.4 mm. Patients were grouped as ‘‘non-synchronized’’ if they had a 
SD above median or if they had only one measurable lesion, and as ‘‘synchronized’’ 
if they had a SD below median. The mean SD of metastatic lesions seemed to be 
lower in the first 3 years after primary surgery, although this trend was not 
statistically significant. As delayed recurrences as well as periods of tumor dormancy 
seem to be more frequent in lymph node negative patients (156, 157) we analyzed 
this group separately. We demonstrated a significantly more synchronized relapse 
pattern in early relapsing, lymph node negative patients compared to late relapsing 
(median 3.1 vs. 5.7, Mann–Whitney test, p = 0.018) and in patients without systemic 
adjuvant therapy (median 2.5 vs. 6.4, Mann–Whitney test, p = 0.005. Fig 5). Also, a 
significant drop in SD was observed at the time of ended adjuvant endocrine 
treatment, comparing between year 4-5, just before ended treatment, and year 5-8, the 
years after (median 13.1 vs. 3.9, Mann–Whitney test, p = 0.021). In the analyses of 
survival, no difference was present for SD of metastases or time between primary 
diagnosis and recurrence. Low tumor load at time of first recurrence, measured by 
sum of diameters of metastatic lesions, demonstrated significantly increased overall 
survival (Log Rank p=0.001). 
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Fig. 5 Metastatic pattern of patients without systemic treatment (N=62). The plots 
show the mean of standard deviation (SD) of size and number of metastases at first 
recurrence (±SE) by time after primary surgery. Box plot of mean SD according to 
early recurrences (0-3 years) versus late recurrences (>3 years). 
Paper II investigated the relapse dynamics after delayed breast reconstruction. 
Median time to reconstruction for the 312 patients was 33 months (range: 1–362 
months). Median follow-up after reconstruction was 137 months. Within 10 years 
after primary surgery, 39 of the 312 reconstructed patients developed local (5), 
regional (6), or distant (31) relapse, compared to 52 patients in the matched control 
group (local 10, regional 3, distant 39). When setting time of origin at reconstructive 
Years after primary surgery












































surgery, we demonstrated a bimodal relapse pattern after delayed breast 
reconstruction in patients treated for breast cancer, similar to that observed after 
primary breast cancer surgery, with peaks at 18 months and five years. The early 
relapse peak was higher in patients undergoing more extensive surgical procedures, 
suggesting a dose-dependent effect. There was no difference in recurrence free 
survival between extensive reconstructive surgery and simple implant surgery (Gray 
test, p = 0.86). Timing of the peak was unaffected, both by extent of reconstructive 
surgery and time interval between primary cancer treatment and reconstruction. 
Known risk factors for recurrence, nodal status and tumor size, affected the height of 
the recurrence peak, but again, not the timing. The new timescale introduced by 
delayed reconstructive surgery demonstrated an increase in hazard ratio for relapse 
for reconstructed patients, compared to matched control patients the first two years. 
After this, the risk seems to be lower, although not statistically significant, thus it 
may not be considered constant (Fig 6). Our results indicate an independent 
stimulating effect of surgery on pre-existing micrometastases, resulting in a transitory 
increased risk of relapse the first two years after reconstruction compared with not 
reconstructed patients, thereafter a decreased risk. Importantly, this did not translate 
into a worse long term disease-free survival for reconstructed patients compared to 




Fig. 6 Hazard rate ratio for recurrence between reconstructed patients and controls in 
relation to time since reconstruction or reference day. Dotted lines represent 95% CI. 
Paper III interrogated the distant metastasis stimulating effect by different second 
surgical procedures. Our hypothesis was that the distant metastasis stimulating effect 
would be different if the second surgery involved removal of a tumor in the breast or 
not. This was based on the assumption that a primary tumor may exert a homeostatic, 
or growth restricting effect on distant metastases and thus the removal of this tumor 
would allow growth of these metastases. Surgery per se has also been demonstrated 
to accelerate metastasis development and our aim was to separate these effects. We 
compared relapse dynamics in 3 databases of patients undergoing second surgery in 
different clinical situations, namely surgery for ipsilateral breast tumor recurrence, 
surgery for contralateral breast cancer and delayed breast reconstructive surgery, 
where no tumor removal is involved. Despite the fact that these patients were accrued 
over a wide time-span, the main prognostic factors are remarkably homogenous, with 
the exception of primary tumor size which was larger in reconstructed patients. In all 
three patients’ series, the relapse dynamics revealed a bimodal pattern with a major 
peak at 18 months and a lower one at 5-6 years. The levels of recurrence risk were 
different. Patients operated for IBTR had the highest risk of developing distant 
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metastasis, the reconstructed patients the lowest and patients operated for a 
contralateral breast cancer an intermediate risk. Also, the time interval from primary 
cancer treatment to second surgery was influential on recurrence risk for surgery 
involving removal of a tumor in the breast, with higher early peaks if the second 
surgery was performed less than three years after primary treatment. For 
reconstructed patients, time from primary treatment did not influence risk of relapse 
(Fig 7). 
 
Fig. 7 Hazard rate for recurrence with T=0 at second surgery. All groups display a 
bimodal pattern with peaks at 18-24 months and 5 years. Time to second surgery 
changes the height of the first peak when tumor removal is involved, but not in 
reconstruction. 
Paper IV further explored the oncological impact of the perioperative period at 
breast reconstruction. The majority of patients, 68%, had at least one reoperation, the 
early reoperations were almost exclusively caused by a complication while later 
reoperations had a higher rate of aesthetic indications. 28% of all patients 
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experienced a complication grade ≥2. In the group undergoing autologous flap 
reconstructions 56% had at least one complication grade ≥2. These patients also had a 
significantly higher rate of reoperations. When exploring relapse dynamics, we 
demonstrated an augmented stimulating effect on relapses in patients experiencing 
complications in the perioperative period as well as in overweight and obese patients.  
The in vivo models have so far failed to produce publishable results. In the first pilot, 
a single mouse displayed lung macrometastases at sacrifice, one of the no surgery 
controls. Micrometastases were not detected in any mice. This led us to doubt the 
behavior of the D2A1-d-cells in our hands, both regarding their ability to extravasate 
and colonize the lung tissue and their dormancy in the absence of stimulation. For the 
second pilot, we took the following measures to address these concerns. First, 
numbers of mice were increased to improve robustness and reliability of the results. 
Second, all cells were labelled with GFP for improved detection of micrometastases, 
and also because GFP has been demonstrated to induce an immune response in 
BALB/c mice (151) potentially resulting in an extrinsically imposed dormancy of 
labelled cancer cells (124). At sacrifice after 6 weeks, 15 of the 19 mice had 
macroscopic orthotopic tumors. The orthotopic tumors were heterogeneous in GFP 
positivity; some were completely negative, while others displayed 20-70% positive 
cells. Lung macrometastases was found in one mouse, this did not stain positive for 








5.1 Discussion of results 
In order to evaluate the importance of tissue trauma and wound healing on metastatic 
relapse of breast cancer we studied patterns and dynamics of breast cancer recurrence 
in relation to patient and tumor characteristics as well as interventions. A theory 
building on a period of tumor dormancy before, during or after primary surgery 
would result in a higher likelihood of finding a solitary metastasis at first recurrence 
than of finding multiple metastases. However, this holds true only by assuming there 
is no synchronized internal clock in the dormant tumor cells and no external signal to 
synchronize growth (158). 
 
For the entire patient series in paper I, there was no significant difference in SD of 
metastatic lesions between early and late relapsing patients, thus it may be considered 
a negative study. As this was a very heterogeneous group regarding patient and tumor 
characteristics, as well as treatment in the primary setting, this should perhaps not be 
surprising. The finding of a significantly lower SD in early relapsing patients with no 
systemic adjuvant treatment suggests that primary cancer surgery may indeed 
synchronize growth of metastases, and that this effect is counteracted by systemic 
treatment. According to treatment guidelines, fewer of the lymph node negative 
patients would be expected to have received systemic adjuvant treatment, this was not 
adjusted for in the analyses in paper I, so the observed difference for this subgroup 
may in part be ascribed to this fact. Furthermore, the distinct drop in SD of 
metastases at the time of ended endocrine treatment both supports the idea of 
systemic treatment acting as a break on dormant micrometastases and serves as proof 
of principle of SD as a marker for synchronized growth. In other words, synchronized 
growth may be a result of either the appearance of a growth stimulating signal like 
surgery, or the removal of a growth inhibitory restraint like systemic adjuvant 
treatment, both assuming the existence of dormant micrometastases. 
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Our work demonstrated a relapse pattern fitting with the idea of synchronized growth 
of dormant metastases in early relapsing, lymph node negative breast cancer patients. 
As a similar recording of size and number of metastases at first relapse has not been 
published, our findings need to be confirmed in other, preferably larger, datasets. This 
may allow for closer analyses of how different subgroups of breast cancer relapse, 
relate distribution of metastases to time and treatment and reveal novel aspects of 
metastasis biology.  
 
To evaluate the possible stimulating effect on breast cancer recurrence by surgical 
trauma and wound healing, we turned to delayed breast reconstruction. This allowed 
us to study this effect in a pure and standardized setting, unaffected by primary tumor 
properties and adjuvant treatment, and with a higher likelihood that any 
micrometastases would truly be dormant as reconstruction is only offered in the 
absence of suspected metastatic disease. This would also circumvent the argument 
that relapses after primary surgery is a result of physical dissemination of tumor cells 
from the breast by the surgical intervention (159). We discovered a relapse pattern 
after delayed breast reconstruction coherent with a stimulating effect of the surgical 
procedure on pre-existing micrometastases. The effect size was dependent on the 
underlying relapse risk of the patient, with higher early peaks in lymph node positive 
patients and with larger primary tumor size. Timing and magnitude were not affected, 
supporting the hypothesis that surgical factors act on the subclinic metastatic state of 
the host. The fact that the hazard rate of later relapses was decreased in reconstructed 
patients further supports the hypothesis that the surgical procedure accelerates growth 
of occult distant micrometastases that would otherwise have appeared at a later time. 
A study by Isern et al found a higher risk of relapse in reconstructed patients 
compared to mastectomy alone, this remained statistically significant in multivariable 
analysis (38). That study, however, suffered from a suboptimal matching of cases and 
controls regarding important prognostic factors such as lymph node status. In our 
study, the pattern of a transitory increase in relapses the first two years after 
reconstruction, followed by a reduction was evident also in the multiple timescale 
multistate model. This model takes into account the joint effect of prognostic factors 
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as well as the effect of the change in hazard rate by specific stimulating events, here 
reconstruction, occurring at different time points.  
 
In accordance with other reports, we found a slightly better long-term outcome in 
reconstructed patients compared to controls (37, 160, 161). The reason for this is at 
present undetermined, but may be explained by higher socioeconomic status and 
lower comorbidity in patients opting for breast reconstructions, factors that are also 
associated with a lower risk of relapse (162). In other aspects, other groups have 
reported contradictory results to ours, with no sign of an acceleration of relapses after 
delayed reconstruction (37). This discrepancy may be caused by a different selection 
of patients for reconstructive procedures in different institutions, or different rates of 
complications to surgery. Indeed, in the study by Geers et al (37), prognostic factors 
were significantly different, in favor of reconstructed patients, regarding age, tumor 
size, and lymph node status compared to controls. They also included implant-based 
reconstructions in the non-reconstruction control group, this was also permitted in a 
similar study with no evident difference in relapses after autologous reconstruction 
(163). The argument was that the surgical trauma is significantly smaller in implant 
based reconstructions compared to reconstructions with autologous tissue flaps. 
While this is undoubtedly true, it may still be above the threshold for a systemic 
effect on dormant micrometastases, potentially obscuring differences between these 
groups. In a large-scale in vivo study, the implantation of a small sponge, and even a 
mere two centimeter cutaneous incision, immediately sutured, was enough to promote 
outgrowth of tumors of mammary gland origin at a distant site in mice (124).  
 
Results from preclinical studies, mainly performed in mice models of breast cancer, 
have provided convincing evidence of a link between inflammation, tissue trauma or 
wound healing and escape from tumor dormancy (111, 124, 138, 139). These include 
both transgenic and syngeneic allograft mouse tumor models. While mouse studies 
have certainly yielded enormous insight into many aspects of tumor biology, species 
differences as well as the representativeness of murine tumors to their human 
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counterparts must be taken into consideration, and results cannot always be assumed 
transferable.  
 
In an attempt to model surgery induced escape from dormancy in vivo in this work, 
we encountered several problems illustrative of the difficulties in modelling 
dormancy. First, in expanding cells in vitro, there is an inherent risk of selecting for 
less dormant and more aggressive clones in each cycle. Even though passaging was 
kept to a minimum, a certain number is inevitable for transduction, expansion, sorting 
etc. The fact that some tumors, both orthotopic and in lungs, had no GFP expression 
while others were composed mainly of GFP positive cells can be due to instability of 
the transduction, or selective advantage of GFP-negative cells in some mice. In vitro, 
the transduction seemed stable, with >95% of cells being positive after two passages. 
The conditions encountered in the complex biologic system of the mice, with fully 
functional immune system, may of course have altered this. Intravenous injection of 
cancer cells to produce lung metastases includes only the later steps of the metastatic 
cascade, assuming that the earlier steps, up until extravasation, have already taken 
place. Surgical trauma in the model did not involve removal of a tumor in the breast. 
This may be considered an advantage as it eliminates variation due to tumor size, 
immune infiltration and vascularization of the primary tumor and thus gives a more 
standardized trauma and wound healing situation. On the other hand, such a model 
does not take into account the possible effect on metastases exerted by the primary 
tumor. Further development of an in vivo model is ongoing in our group. 
 
To explore the effect on oncologic outcome of different events and conditions at 
reconstructive surgery, we investigated surgical and medical complications, patient 
factors like comorbidity and BMI at reconstruction in our cohort, presented in paper 
IV. We discovered a surprisingly high rate of reoperations and complications in all 
patients, and particularly patients undergoing autologous flap reconstructions. We 
showed that complications in the perioperative period, as well as overweight and 
obesity, add to the metastasis relapse accelerating effect, further establishing the 
perioperative period as important to metastasis biology.  
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In paper III we demonstrated relapse dynamics following subsequent surgeries after 
breast cancer treatment to be similar to the dynamics previously reported after 
primary tumor surgery. Again, we saw that the surgical procedures exerted their 
effects on the underlying risk of relapse of the patients, IBTR (ipsilateral breast tumor 
recurrence) being a well-known risk factor for developing distant metastases; 
coherently, these patients had the highest hazard rate for relapses. The fact that the 
patients’ series in paper III differ in the primary treatment needs some careful 
consideration. On the one hand, it may be considered a limitation as all patients in the 
reconstruction series were treated with mastectomy while patients experiencing an 
IBTR had breast conserving surgery in the primary setting and CBC (contralateral 
breast cancer) patients where a mix of the two. Thus, the varying effects observed in 
relapse dynamics after second surgery may be attributed to events in the primary 
treatment. On the other hand, the fact that we still observe such similar relapse 
dynamics after second surgical procedures, despite different primary treatment can be 
taken as support of the conclusion that this is actually an independent stimulating 
event. The difference in how time between first and second surgery affects the risk 
level for patients undergoing surgical excision of a tumor in the breast but not in 
reconstructive surgery, suggests two separate effects on distant dormant metastases: 
one of tissue trauma and wound healing per se and another of the removal of a growth 
restraining tumor. 
 
It has been suggested that the early peak in relapses may be a statistical artefact, 
caused by more frequent follow-up in the time after surgery and thus an accumulation 
of relapses in this time period, while later relapses, and relapses in no surgery 
controls, may go undetected for a varying length of time, resulting in a more even 
distribution. While this might be true for locoregional relapses, follow-up does not 
include imaging or biochemical analyses directed at detecting distant metastases. 
Indeed, it has been demonstrated that even when adopting more extensive follow-up 





All our data are based on extensive patient and tumor characteristics, for paper I and 
II extracted from clinical records, by the authors, and are thus both comprehensive 
and reliable. Biochemical measurements and radiological imaging come from the 
hospital patients’ records and are thus produced by equipment and protocols verified 
and calibrated to the high standards required for clinical use. The IBTR and CBC 
groups in paper III come from randomized controlled trials with thorough and 
systematic recording of clinical data. The long follow-up time, over ten years for all 
studies on relapse dynamics, is another strength, one necessary to be able to properly 
evaluate relapse dynamics for patients with such good prognosis, and when aiming at 
studying tumor dormancy. The relapse pattern of breast cancer, with a bimodal 
distribution of relapses, as well as the timing of relapse peaks is very similar to 
publications from other institutions. 
5.3 Limitations 
The main limitation of our studies is their retrospective nature precluding any 
conclusions regarding causality. The relatively small number of patients is another 
major limitation, giving wide confidence intervals, diminishing the external validity 
of results and the possibility of extensive subgroup analyses. Locoregional relapses 
may be diagnosed at routine breast cancer follow up, distant metastases, however, are 
usually detected when they cause symptoms, as follow up in Norway does not include 
imaging or blood sampling to detect biochemical alterations. Timing of metastatic 
development is heterogeneous, and patients vary in their tendency to seek medical 
advice when experiencing symptoms, thus metastases may have been present for a 
short or long time when diagnosed, this limits the accuracy of our estimations of 
timing of relapses. 
 
 61 
As most analysed patients in our studies were treated before the introduction of HER2-
directed therapy, data on HER2-status was unavailable for the vast majority of patients, 
preventing specific subgroup analyses on the triple-negative cancers. 
 
The highest level of evidence to support or refute a link between physical trauma and 
relapse of cancer would have to be obtained from randomized controlled trials (164). 
Such a trial on surgery induced metastatic relapse, however, is hardly feasible, neither 
regarding ethical approval or patient inclusion. Accumulated retrospective data, from 
well matched series of cases and controls, supported by pre-clinical investigations, 















In conclusion, this work demonstrates that tissue trauma and wound healing can have 
an impact on distant relapse dynamics in breast cancer. In our material, the effect is 
modulated by extent of surgical trauma as well as the patients’ inherent risk as 
determined by tumor and patient properties. In paper I we proposed SD of metastases 
at first relapse as a marker of synchronized growth, and demonstrated lower SD of 
metastases in early recurrent, lymph node negative patients and in patients not 
receiving adjuvant systemic treatment, coherent with a growth synchronizing effect 
of primary tumor surgery. In paper II we demonstrated an acceleration of relapses 
after delayed breast reconstruction resulting in a distinct peak 18 months after 
reconstruction. This effect was more evident in patients with higher pre-existing risk 
of relapse, and in patients undergoing more extensive reconstructive procedures. In 
paper III, we found similar relapse dynamics with peaks at 18 months and 5-6 years 
after second surgery in breast cancer treated patients, regardless of whether the 
surgery included removal of a tumor in the breast or not. The time interval between 
first and second surgery modulated the effect when a breast tumor was removed, 
leading to a higher first peak in early relapsing patients. The effect on distant 
metastasis dynamics of reconstruction was unaffected by time interval. This supports 
the theory of two separate effects on distant metastasis, one by surgery and wound 
healing per se, and another by disrupting tumor homeostasis. Paper IV supports the 
perioperative period as biologically important for oncologic outcome by the 
relationship between complications to reconstructive surgery and further acceleration 
of relapses. It also showed that host factors such as overweight and obesity modulates 
this effect, possibly by an inherent low grade systemic inflammation associated with 
these conditions. In total, this work demonstrates an impact of tissue trauma and 
wound healing on relapse patterns and dynamics in breast cancer, which may be 
explained by stimulated escape from dormancy of occult micrometastases, warranting 




7. Future perspectives 
The field of tumor dormancy has been intriguing scientists for a long time, but it is 
only in the last few decades that this phenomenon has been the focus of systematic 
pre-clinical, clinical and epidemiological studies. We are only scratching the surface 
of this elusive property of some cancers, including how to detect and manage it. In 
our view, accumulated evidence, since the pioneering work of Bernhard Fisher up 
until today, compels us to regard breast cancer as a systemic condition, with the 
patient potentially harboring multiple micrometastases, even before the detection of 
the primary tumor. These minuscule cancer deposits are, as all cells and tissue, 
susceptible to events and signals in the body. Surgery is, and has for centuries been 
the main pillar in breast cancer treatment. If, as we and others suggest, surgical tissue 
trauma can indeed awaken dormant micrometastases, it would be a violation against 
the first principle of medicine, primum non nocere, first do no harm.  
 
With increasing understanding of metastasis biology, adjuvant local and systemic 
treatment have improved outcome for breast cancer patients substantially. In the late 
20th and early 21st century, neoadjuvant preoperative treatment was introduced, and 
its benefit is seen in a number of patients. The systemic impact of events in the 
perioperative period, however, is only beginning to be explored, and may be an area 
with potential for substantial improvement in patient outcome. Our group has studies 
in the pipeline of interventions around the time of surgical procedures in cancer 
patients to prevent the possible detrimental, unintentional effects of tissue trauma and 
wound healing. 
 
We and others have presented convincing results of an impact on distant metastasis 
development by surgery, fitting with an induction of escape from tumor dormancy. 
The detection of a tiny metabolically inactive, non-dividing cell or group of cells in 
the human body is inherently difficult. Catching it at the time it transits from this 
dormant state to proliferation, in order to study the nature of this escape is perhaps 
even more challenging. Fortunately, we, and scientists across the world, are willing to 
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face this challenge. Results by our group and others are not yet mature to change 
recommendations for clinical practice, regarding breast reconstruction or other 
surgical procedures in patients potentially harboring occult, dormant 
micrometastases. As this link is being further characterized and understood, we 
anticipate discovery of targets for intervention, and thus development of preventive 
medications to maintain the disseminated tumor cells in a dormant state throughout 
the patients’ lifespan, or even to eradicate the dormant cancer cells to ensure freedom 
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Abstract A significant variation in the metastatic pattern
among breast cancer patients exists. Clinical observations
suggest that these differences are related to time to recur-
rence (TTR), thus suggesting a common systemic growth
signal at the time of surgery. Our goal was to identify a
marker for synchronized growth of micrometastases. To
quantify the metastatic pattern at first relapse, 180 patients
with metastatic breast cancer were studied. Standard
deviation (SD) of lesions size and lesion number was cal-
culated and served as a marker for variation. Patients with
low SD (multiple/similar sized lesions) were assumed to
have synchronized growth, whereas patients with high SD
were assumed to have unsynchronized growth. Patients
were grouped according to TTR; early (\ 3 years-) or late
([ 3 years- after surgery). In patients not receiving sys-
temic adjuvant treatment, median SD was significantly
lower in the early group (2.5 mm) compared with 6.4 mm
in the late group (p = 0.005). In node negative patients,
median SD was significantly lower in the early group
(3.0 mm) when compared with the late group (5.7 mm,
p = 0.02). An additional drop in SD was observed imme-
diately after end of adjuvant endocrine therapy. Our results
identify SD as a marker of synchronized metastatic growth
in breast cancer. A metastatic phenotype characterized by
multiple similar sized metastases, suggesting synchronized
onset of growth of micrometastases was predominantly
found in patients recurring early after surgery and was
counteracted by adjuvant treatment. Systemic growth sig-
nals caused by surgery might be antagonized during the
time window following surgery.
Keywords Breast cancer  Surgery  First relapse 
Metastases  Radiology  Adjuvant treatment  Metastatic
pattern  Tumor dormancy
Introduction
Breast cancer has a long natural history and is infamous for
its propensity for late relapses when compared with most
other cancer types [1]. Even clinically undetectable, tiny
tumors can shed malignant cells into the circulation. Sev-
eral biomarkers like ER, Her2, TNM-classification, and
gene expression signatures [2–5] can readily be applied to
predict early local or early distant disease recurrence within
5 years of diagnosis. On the other hand, no biomarkers
have been proven clinically useful to predict late relapse [6,
7]. In cases with delayed relapse, the nonlinearity of dis-
ease progression gives an indication of the presence of
periods with tumor dormancy [8, 9]. Early micrometastatic
foci, single cells, clusters of cells, or microscopic tumors
can be restricted in growth over periods of time by inability
to recruit blood vessels [10], by immunesurveillance [11],
by cell cycle arrest [12], by tumor microenvironment
(TME) interactions [13] as well as by iatrogenic depletion
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of growth stimulatory hormones in the case of ER? breast
cancer [14]. Interestingly, there are several experimental
tumor models suggesting that dormant cancer can turn into
rapidly progressing disease by growth systemic signals [8,
15, 16]. Moreover, systemic growth signals caused by tis-
sue trauma and wound healing has been shown to initiate
and synchronize growth of dormant micrometastases [17,
18]. Also clinical consequences of tissue trauma and
wound healing have been discussed, as recently reviewed
by Ceelen et al. [19]. Although controversial, in a series of
clinical studies on human breast cancer, Demicheli et al.
[20–22] suggest that the tissue trauma caused by the pri-
mary surgery alone is able to alter the growth kinetics of
dormant micrometastases and reduce time to recurrence.
We hypothesize that activation of systemic growth sig-
nal cascade in breast cancer patients with dormant mi-
crometastases might result in synchronized growth and thus
the detection of multiple similar sized macrometastases at
the time of first recurrence. Consequently, the detection of
multiple similar sized metastases might serve as a marker
of synchronized growth kinetics in these patients. In con-
trast, detection of solitary metastases or oligometastases
with large size variation is more likely to occur when the
metastases grow independently in the absence of a syn-
chronizing signal. In the present study, we aimed to
quantify size and number of metastatic lesions in relation to
time between primary surgery and first relapse. We further
hypothesized that growth of dormant micrometastases can
be preceded by a synchronizing event like increased levels
of wound healing associated growth factors following
surgery or sudden withdrawal of anti-endocrine therapy.
Moreover, we suggested that metastatic synchronization
can be quantified by the standard deviation of size and
number of metastases at time of first recurrence, as a
marker of variation in the metastatic pattern. We focused
on two clinically relevant candidate events that could lead
to systemic synchronization of dormant micrometastases
common to a majority of breast cancer patients; wound
healing after primary surgery and cessation of endocrine
adjuvant therapy.
Methods
The study base for this retrospective analysis consists of 209
consecutive patients treated for metastatic breast cancer
between January 2005 and December 2009 at the Depart-
ment of Oncology, Haukeland University Hospital, Norway.
The hospital covers a population of 500,000, and all new
diagnosedmetastatic breast cancer patients in the population
are referred to the regional center. All patients registered
with an ICD-10 code for breast cancer (C 50.X) aswell as one
or more codes for metastases (C 77.X–C 79.X) were iden-
tified and all diagnoses were verified and validated in the
patient records. Time to recurrence (TTR) was recorded as
time between primary surgery and time of occurrence of first
recorded metastasis. Patients with synchronous metastases
and primaries, patients with evidence of metastatic disease
within 2 months of surgery, patients that did not have their
primary tumor removed, local recurrences, and patients with
secondary (non-breast) cancers were excluded. Cases with
measurable metastatic disease according to RECIST 1.1,
modified by inclusion of both lytic and blastic bone lesions,
were studied. Blastic bone metastases occur frequently in
breast cancer and were regarded as evaluable for the pur-
poses of this study. Thus, 180 patients were available for
analyses of metastatic pattern.
At the time of first relapse, all patients underwent
thorough staging with radiology, biochemistry, and clinical
examination. Most patients were subjected to multiple
radiology modalities like CT-scan, bone scan, MRI, ultra-
sound, and chest X-ray. All radiology and clinical tumor
measurements were re-examined and the following vari-
ables were recorded; radiology modality, size of each
metastatic lesion according to modified RECIST 1.1,
number of metastases, and affected organs. Patients with
more than 10 metastases were recorded as ‘‘[10’’. For each
case, the standard deviation (SD) of the different sizes of
the metastases was calculated. SD was used as a marker for
variability in the metastatic pattern. Thus, a patient with
multiple similar sized metastases at the time of first
recurrence would present with a ‘‘low SD’’ (Fig. 1a),
whereas a patient with, i.e., one large and two small
metastases would have a ‘‘high SD’’ (Fig. 1b?c). Patients
with solitary metastases (n = 41, 23 %) were excluded
from analyses of SD. No patients underwent metastasec-
tomy. To justify for the effect of tumor size on SD, we also
examined the potential use of alternative metric measures
of the metastases (SD divided by sum of diameters, SD
divided by mean diameter, SD divided by the square root
of the mean as well as SD divided by log mean) for their
potential use as markers for synchronized growth.
The median value of SD was used as cut-off value and
patients, were grouped as ‘‘low SD’’ and ‘‘high SD’’,
accordingly. Associations between different categorical
variables were assessed by Pearson’s Chi-square test.
Continuous variables not following the normal distribution
were compared between two or more groups using the
Mann–Whitney U tests. Univariate survival analyses were
performed by the product-limit procedure (Kaplan–Meier
method). Differences between categories were tested by the
log-rank test.
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Results
The key demographics and pathologic and clinical char-
acteristics of 180 patients recorded at the time of first
recurrence are shown in Table 1. A majority of the patients
were Stage 1–2 (88 %), ER ? (77 %), Her2- (77 %).
Bone- (38 %), lung- (30 %) and liver metastases (23 %)
were the most frequent metastatic sites. For the majority of
the patients (58 %), a CT-scan was the most appropriate
modality for tumor size measurements. For patients with
bone metastases, MRI (30 %) was the preferred modality,
whereas ultrasound (lymph nodes) and x-ray (bone
metastases and MRI contraindications) were used in some
cases (12 %).
Median time to recurrence was 53 months (2.6–305),
and no significant difference was present according to
stage, primary tumor grade, or Her2 status in this popula-
tion. ER negative patients (Log Rank p\ 0.001) and
younger patients (below median) (Log Rank p = 0.01) had
significantly shorter time to recurrence, median 28 versus
62 months and median 42 and 69, respectively. The annual
hazard rate of recurrence for the whole study population is
shown in Fig. 2.
Initially, we investigated the number and size of detec-
ted metastases in our patient population. The median
number of lesions measured was 7 (mean 6). Still, some
patients presented with more than 10 lesions and were
recorded as ‘‘[10’’, accordingly. Forty-one (23 %) patients
had only one measurable lesion at the time of first recur-
rence. Thus, SD was available in 142 patients. Median SD
in the population was 5.4 mm. Patients were grouped as
‘‘non-synchronized’’ if they had a SD above median or if
they had only one measurable lesion, and as ‘‘synchro-
nized’’ if they had a SD below median. Median sum of
diameters of metastatic lesions was 76 mm (10–697)
(Table 2).
We then analyzed in each patient the SD of metastatic
lesions in relation to time to recurrence. As illustrated in
Fig. 3a?b, the mean SD of metastatic lesions seemed to be
lower in the first 3 years after primary surgery, although
this trend was not statistically significant. Moreover, as
delayed recurrences as well as periods of tumor dormancy
are more evident in the node negative patient [23, 24], we
analyzed this group of patients separately. In this subset of
patients, there was a significantly lower SD in patients who
experienced early disease recurrence (B 3 years) when
compared to those with delayed recurrence[ 3 years
(median 3.1 vs. 5.7, Mann–Whitney test, p = 0.018)
(Fig. 3c?d). Similarly, SD was significantly lower during
the first three years after primary surgery in patients not
receiving systemic adjuvant treatment (median 2.5 vs. 6.4,
Mann–Whitney test, p = 0.005) (Fig 3e?f). There was no
significant association between SD and time after surgery
in patients receiving adjuvant systemic treatment.
Adjuvant endocrine treatment might affect the growth
kinetics of dormant micrometastases. Consequently, we
asked if a second drop in SD occurred at the time of
withdrawal of endocrine treatment (5 years of tamoxifen or
aromatase inhibitors). As expected, following the end of
endocrine treatment at year 5, there was a second drop in
SD (Fig 4a). When comparing the period just before end of
endocrine treatment (year 4–5) with the period immedi-
ately after end of endocrine treatment (year 5–8) SD was
significantly lower in the latter period (median 13.1 vs. 3.9,
Mann–Whitney test, p = 0.021, Fig 4b).
Low SD was significantly associated with low histo-
logical grade in primary tumors (Pearson Chi Square
p = 0.002), the absence of liver metastases (Pearson Chi
Fig. 1 Patient with multiple similar sized metastases at the time of
first recurrence and with low standard deviation (SD) of size and
number of metastatic lesions (a). Patient with one large liver
metastasis (red line) and two small metastases lung metastases at
the time of the first recurrence (only one is shown here, red arrow)
and with high SD (b, c)
Breast Cancer Res Treat (2014) 146:627–636 629
123
Square p = 0.001), and the presence of lung metastases
(Pearson Chi Square p = 0.02). No statistically significant
association was found between SD and ER status, Her2
status, radiology modality, nodal status, or stage. Other
metric measures of themetastases (seemethods) did not give
significant information in addition to the analyses of SD.
Table 1 Patient characteristics













T1 (\2 cm) 74 41
T2 (2–5 cm) 92 51



































Number of patients Percent
Brain 9 5
Other 21 12
Key demographic and pathological characteristics including age,
nodal status, tumor size, stage, grade, HR status, and Her2 status at
the time of primary surgery in 180 patients recorded with metastases
from breast cancer during 2005–2009 at Haukeland University Hos-
pital, Norway
a Refers to the radiology modality used for the analysis of metastases
number and size
b Ultrasound, chest x-ray, clinical measurement (caliper)
Months after primary surgery























Fig. 2 Annual recurrence hazard rate (± SE) in 180 patients
recorded with metastatic breast cancer at Haukeland university
Hospital during 2005–2009
Table 2 Metastatic pattern
Median Mean Min–max
Number of lesions counteda 7 6 1–[10
P
diameter of lesions per case (mm) 76 99 10–697
Standard deviation of lesions
per case (mm)
5.4 8.3 0–58
Time to recurrence (months) 53 69 2.6–305
Analysis of metastatic pattern at first recurrence in 180 cases of
metastatic breast cancer treated at Haukeland University Hospital,
Norway. Tumor measurements are in accordance with RECIST 1.1
a If[10 lesions, n = 10
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Finally, in the analyses of overall survival between time
of first recurrence and death, significantly increased sur-
vival was present in ER ? cases (Log Rank p = 0.05),
Her2 positive cases (Log Rank p = 0.008) as well as in
cases with low tumor load as measured by sum of diame-
ters of metastatic lesions at time of first recurrence (Log
Rank p = 0.001). No survival differences were present for
SD, liver metastases, lung metastases, stage at primary
diagnosis, or time between primary diagnosis and
recurrence.
Discussion
This study was initiated following the clinical observation
of variation in metastatic patterns in patients referred to our
ward at the time of first metastatic recurrence from breast
cancer. Whereas some patients presented with solitary or
oligometastases of varying size, other patients showed
multiple similar sized metastases in one or more organs.
We further observed that patients in the latter category
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Fig. 3 Metastatic pattern in 180 breast cancer patients. The plots
show the mean of the standard deviation (SD) of size and number of
metastases in each patient at first recurrence (± SE) according to time
after surgery. a All cases. b Box plot of mean SD according to early
recurrences (0–3 years) versus late recurrences (3 ? years), all cases.
c, d Node negative cases e, f Cases with no systemic adjuvant
treatment. *Mann–Whitney test
Breast Cancer Res Treat (2014) 146:627–636 631
123
after primary surgery, shortly after delayed breast recon-
struction, or shortly after end of adjuvant endocrine treat-
ment. Delayed recurrence of breast cancer metastases is
frequently observed in patients with estrogen receptor (ER)
positive disease in particular [5]. An annual recurrence rate
of 2 %, for as long as 15 years even after 5 years of
tamoxifen [25] or aromatase inhibitors [26], prevents these
patients from considering themselves as cured even for
decades.
The prominent variation in time between primary sur-
gery and first relapse in breast cancer suggests that there is
a great heterogeneity among patients or in the inherent
biology of the tumor cells per se. In some cases, a steady
growth of metastases and a constant risk of relapse can be
inferred by modeling the time of primary tumor detection
in relation to the time of relapse as well as the size and
number of metastases [27]. In addition, tumor dormancy
also in primary tumors is frequently found in the breast, the
prostate, and the thyroid gland of undiagnosed patients in
various autopsy materials [28], further supporting the
existence of growth inhibiting mechanisms or the absence
of growth stimulating signals.
In spite of otherwise favorable prognosis when com-
pared with node positive (N?) patients, some node nega-
tive (N0) patients do relapse with metastatic tumor growth.
In large patient series, the relapses observed in the node
negative patients also show a tendency of occurring later
when compared with node positive patients [23, 24]. Even
tiny tumors might eventually recur at distant sites in spite
of radical surgery at the primary stage. The station by
station model of breast cancer progression put forward by
Halsted over a century ago [29] followed by large and
mutilating ultra-radical surgery procedures has been
replaced by less invasive methods [30–33]. Recently, also
the value of lymph node dissection even in sentinel node
positive patients has been challenged [34]. The multimodal
approaches including limited surgery with immediate
reconstruction, limited irradiation, and effective systemic
adjuvant therapy, presently give the best total outcome
regarding both survival and quality of life. Nevertheless, in
spite of all the recent achievements in the treatment of
primary breast cancer, about 10 percent of patients even-
tually relapse [35]. Even if the concept of tumor dormancy
in breast cancer seems to be well established, several
controversies concerning the clinical impact exist [36].
Little is known about what mechanisms control dormancy
in human micrometastatic disease, and even more impor-
tant; what physiologic processes can cause the suspension
of dormancy and thereby fatal disease relapse. The Gom-
pertzian model of human breast cancer growth as discussed
by Norton [37], or more complicated models as suggested
by Speer et al. [38], can predict progression of the unper-
turbed primary tumor and are widely applied in the plan-
ning of adjuvant trials. Several mathematical models have
been applied to describe different relapse scenarios with
regard to time, size, and number of metastases [27, 37, 39].
Still, the lack of knowledge on the mechanisms controlling
tumor dormancy and tumor growth spurts renders these
models as crude approximations when it comes to pre-
dicting relapse in individual patients. The typically highly
variable remission periods between resection and relapse in
breast cancer patients are inexplicable by continuous
growth of metastases [40–42] and imply some degree of
growth restriction of occult micrometastases.
In theory, assuming a situation with a period of tumor
dormancy before, during or after primary surgery, the
likelihood of finding a solitary metastasis at the time of first
recurrence is statistically higher than finding multiple
metastases. This assumption is valid only if there is no
synchronized internal clock in the metastatic tumor cells or
no systemic signal to synchronize metastatic growth. Still,
in the clinic, we frequently observe patients with multiple
Cases with 5 years adjuvant 
endocrine treatment
Years after primary surgery
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Fig. 4 Metastatic pattern in the subgroup of breast cancer patients
treated with adjuvant endocrine therapy. a Mean of the standard
deviation (SD) of size and number of metastases in each patient at
first recurrence (± SE) according to time after surgery. b Box plot of
mean SD compared between the time before versus after cessation of
adjuvant endocrine treatment. *Mann–Whitney test
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similar sized metastases at first recurrence even many years
after removal of the primary tumor. These observations
support the concept that there might be a systemic event
simultaneously breaking the dormant state of micrometas-
tases. In addition to immunosuppression [11] and hormone
deprival [14], it has been suggested that wound healing
following the primary surgery might be one such syn-
chronizing signal, by turning on the angiogenic switch in
dormant micrometastases and thereby activating angio-
genesis [16–18]. The frequently observed peak in the
hazard ratio of relapse around 18 months, independent of
primary tumor stage [20, 25, 43], has been attributed to the
systemic response to primary surgery of breast tumors [44].
In order to find clinical support for a possible association
between time of primary surgery and synchronized growth
of dormant micrometastases, we studied the metastatic
pattern in 180 breast cancer patients at the time of first
recurrence. We established the SD of the measured sizes of
the metastases as a potential marker for synchronized
growth. It is a possible drawback in our material that our
patients, in most cases, presented with symptoms or bio-
chemical alterations before the diagnosis of recurrence was
established. In Norway, there is no requirement for routine
radiological examinations during follow-up. Thus, our data
does not give exact information on how long the lesions
might have been detectable by radiology ahead of diag-
nosis, nor of the growth rate. There is a possibility that the
power of SD as a marker for synchronized growth is
diluted by this weakness. Still, as a marker to identify cases
with low variation versus high variation in number and size
of metastases (i.e., synchronized vs. non-synchronized), SD
was superior to other metric estimates (see methods) by
computational simulation, especially when a Gompertzian
growth pattern was assumed. Nevertheless, there is a pos-
sibility that the size dependency of SD makes direct
comparison between the very small and the very large
metastatic lesions inaccurate. To our knowledge, this
approach has not been previously reported, and thus needs
to be confirmed in separate datasets.
We found that the SD was lower in early recurrences
(0–3 years after surgery), and this difference was statisti-
cally significant in node negative patients. The difference
between the node negative and the node positive patients
might be due to the difference in the overall prognosis. In
node positive patients, the micrometastatic spread is fre-
quently more advanced at the time of primary surgery and
the growth into macrometastases might already have been
initiated. In contrast, regarding the node negative patients,
our results indicate that the dormancy of systemic mi-
crometastases seems to be more susceptible to a systemic
synchronizing growth signal. This is in line with the
observed delayed recurrences in node negative patients in
large patient materials [23, 24]. Sixty-five percent of our
patients received systemic adjuvant treatment after primary
surgery. The sole intention of this treatment is to prevent or
at least delay growth of micrometastases, and this effect
was also reflected in a significantly lower SD in early
recurrences observed in cases not given adjuvant treatment.
This finding might suggest that adjuvant systemic treat-
ment prevents the effect of the synchronizing systemic
signal on the tumor cells during the time immediately after
surgery. Importantly, delayed initiation of adjuvant che-
motherapy has recently been shown to be associated with
significantly worse outcome [45], further underlining the
importance of the time window immediately following the
surgical procedure. We also cannot rule out the possibility
that the association between SD and time to recurrence
found in node negative cases is, in part, due to the
increased use of adjuvant treatment in node positive cases.
As expected, there was a second drop in SD directly after
end of adjuvant endocrine treatment in ER ? patients.
From this, we might infer that the removal of the estrogen
receptor or aromatase inhibitors acts as a second systemic
signal to synchronize growth of occult micrometastases
kept dormant during estrogen deprival. This expected
finding also serves as an internal control for the utility of
SD as a marker of synchronized growth. In comparison to
ER-, the ER? population recurs later [1], and this was
also the case in our study. An alternative explanation for
the delayed relapse and prolonged dormant state of the
slow growing ER? tumors could be the requirement of an
spontaneous enabling sub-clonal evolution in these cells
[46], which would occur independently in individual cells
over time. The subsequent macrometastases are then likely
to be asynchronous. Still, there was no significant associ-
ation between ER status and SD. This suggests that syn-
chronization occurs at a similar rate in ER positive and
negative patients. Low SD correlated with low histologic
grade in the primary tumors and suggests that synchronized
metastatic growth is more frequent in cases with lower
tumor heterogeneity. Still, no significant association
between histologic grade and time to recurrence was found.
Synchronized growth, quantified by low SD, showed an
inverse association in lung metastases and liver metastases.
Whereas in the lung, the SD was found to be lower when
compared with other sites, SD was significantly higher in
the liver, suggesting a different growth dynamic between
different organs. Still, most of our patients presented with
lesions at multiple sites. In a recent report by Cummings
et al. [47] 197 autopsies on patients that died of breast
cancer were examined in detail. Of a total of 150 patients,
the 46 patients who underwent surgical treatment of the
primary tumor were significantly more likely to develop
liver metastases, suggesting a role of acute wound healing
Breast Cancer Res Treat (2014) 146:627–636 633
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after surgery in activating dormant micrometastases in the
liver. Similar findings have also been reported by others
[48]. Experimental studies have also reported the role of
post-surgical wound healing in stimulating growth of liver
metastases [16]. Levels of wound healing associated
growth factors like Vascular Endothelial Growth Factor
show great heterogeneity between patients and also
between peripheral blood and locally at the wound site
[49]. Studies also show that levels of angiogenesis inhibi-
tors might change following surgery or radiation therapy of
the primary tumor [50, 51].
The effect of surgery on macrometastases has been an
unresolved issue addressed in multiple retrospective trials
studying the impact of removal of the breast in patients
with stage IV disease at presentation [52, 53]. Still, sev-
eral of these trials have been significantly biased based on
inclusion criteria. Nevertheless, surgical treatment in
patients with synchronous metastases is frequently rec-
ommended to increase local control, although overall
survival benefit remains to be proven [53]. Recently, a
clinical study on 350 women with stage IV disease at
presentation, randomized between surgical removal of
primary tumor and axillary lymph nodes and systemic
therapy, or systemic therapy alone, was presented by
Badwe et al. [54]. Although a significant increase in local
control was found, the distant site progression free sur-
vival was significantly decreased after surgery. Thus,
suggesting a detrimental effect of the surgical procedure,
as put forward by Fisher et al. [55]. No difference in
overall survival was found.
In conclusion, our results identify the standard deviation
of number and size of metastases at first recurrence as a
marker of synchronized growth of breast cancer metasta-
ses. Furthermore, significantly lower SD in early recur-
rences in node negative patients and patients not given
adjuvant systemic treatment suggests a link between the
surgical procedure and early synchronized metastatic
growth, which might be inhibited by systemic adjuvant
treatment. Further research that aim to identify the sys-
temic growth signals caused by surgery and wound healing,
might open additional therapeutic opportunities during the
time window around or immediately after surgical
intervention.
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Abstract The purpose of this study was to characterize the
recurrence dynamics in breast cancer patients after delayed
reconstruction. We hypothesized that surgical reconstruc-
tion might stimulate dormant micrometastases and reduce
time to recurrence. All mastectomy breast cancer patients
with delayed surgical reconstruction at Haukeland
University Hospital, between 1977 and 2007, n = 312,
were studied. Our control group consisted of 1341 breast
cancer patients without reconstruction. For each case, all
patients in the control group with identical T and N stages
and age ±2 years were considered. A paired control was
randomly selected from this group. 10 years after primary
surgery, 39 of the cases had relapsed, compared to 52 of the
matched controls. The reconstructed group was analyzed
for relapse dynamics after mastectomy; the first peak in
relapses was similarly timed, but smaller than for the
controls, while the second peak was similar in time and
size. Second, the relapse pattern was analyzed with
reconstruction as the starting point. A peak in recurrences
was found after 18 months, and a lower peak at the 5th–6th
year. The height of the peak correlated with the extent of
surgery and initial T and N stages. Timing of the peak was
not affected, neither was the cumulative effect. The relapse
pattern, when time origin is placed both at mastectomy and
at reconstruction, is bimodal with a peak position at the
same time points, at 2 years and at 5–6 years. The timing
of the transition from dormant micrometastases into clini-
cally detectable macrometastases might be explained by an
enhancing effect of surgery.
Keywords Breast cancer  Surgery  Breast
reconstruction  Recurrence dynamics  Tumor dormancy 
Multivariate regression
Introduction
The major cause of breast cancer mortality is metastatic
disease, and the prevention of metastatic spread and growth
is the aim of primary local and systemic therapy [1]. Still,
after initial treatment with curative intent, breast cancer is
known for its potential to cause late relapse. Even tiny
tumors, undetectable by physical, biochemical, or radio-
logical examination, can shed malignant cells into the
circulation and eventually cause recurrences up to 20 years
after the primary surgery [1]. The current view of breast
cancer as a systemic disease at the time of diagnosis was
introduced by Fisher in the late 1960s [2]. The concept of
tumor dormancy has been proposed [3–6] as an explanation
of the latency of metastatic disease, and the past and cur-
rent research is beginning to unravel the mechanisms of
maintenance as well as disruption of dormancy [7]. Early
micrometastatic foci can be restricted in growth over
periods of time by inability to recruit blood vessels [8], by
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immune surveillance [9, 10], by cell cycle arrest [11], or by
tumor–microenvironment (TME) interactions [12].
Signs of stimulation of micrometastases after surgical
intervention have been observed in experimental and epi-
demiological studies and evaluated in mathematical models
[13–15]. Furthermore, clinical investigations support an
enhancing effect on the growth of metastases after surgical
primary tumor removal [16, 17]. Tissue trauma and sub-
sequent wound healing have been shown to cause both
local and systemic growth signaling cascades, and might
thereby possibly alter the dormant state of occult
micrometastases [18, 19]. In a previous study, our findings
indicated the presence of synchronized tumor growth in
metastatic breast cancer [20]. In some reports on human
cancers such as primary breast cancer [21], ovarian [22],
colorectal [23], lymphoma [24], and others, tissue trauma
has been associated with tumor progression. It was pro-
posed that the primary surgery by itself can represent a
stimulating event responsible for the peak in the incidence
of metastatic disease observed around 2 years postopera-
tively independent of tumor stage [25–27]. In light of these
findings, questions have been raised regarding the safety of
delayed reconstructive surgery. Both increased and reduced
risk of recurrence was reported after delayed breast
reconstruction [28, 29]. The aim of the present study was to
characterize the recurrence dynamics in breast cancer
patients that underwent delayed reconstructive surgery. We
hypothesized that delayed reconstructive surgery might
stimulate preexisting, occult dormant micrometastases and
alter the recurrence dynamics.
Patients and methods
Study population
The study population for this retrospective analysis consists
of all mastectomy breast cancer patients who underwent
delayed reconstructive surgery at Haukeland University
Hospital, Bergen, Norway, and had their primary treatment
between 1977 and 2007. The respective reconstructive
procedures were implant surgery, implants combined with
flaps, deep inferior epigastric perforator (DIEP) flaps, and
transverse rectus abdominis myocutaneous (TRAM) flaps.
Distinction was not made between single- and multistage
surgery. Altogether, 312 patients were included after
exclusion of patients for whom both tumor size and nodal
status were not known as well as patients with secondary,
nonbreast cancers and DCIS (ductal carcinoma in situ)
(Fig. 1). The hospital covers a population of 600,000, and
in this period, all late reconstructive surgical interventions
following breast cancer in the region were performed here.
Each patient’s record was studied to validate diagnosis,
patient and tumor characteristics, adjuvant therapy, time
and type of reconstructive surgery, time of first recurrence,
and recurrent site.
Control group
We received a control population from the Norwegian
Cancer Registry comprising 1341 patients with breast
cancer surgery in the same time period that had not
undergone reconstructive surgery. Reporting breast cancer
treatment to this registry is mandatory for all physicians in
Norway, and the latest published evaluation from 2007
showed a 99 % completeness of data [30]. For data quality
purposes, patient’s records were studied for validation of
diagnosis, patient and tumor characteristics, adjuvant
therapy, reconstructive surgery (excluded from the control
group), time of first recurrence, and recurrent site in the
same way as was done with the cases. Among the 1341
patients, a total of 473 patients were excluded (see Fig. 1
for details) leaving 868 patients, whose characteristics are
shown in Table 1, which hereafter will be labeled ‘‘control
group.’’
Matching
For each patient in the reconstruction group, all patients in
the control group with identical T and N stages,
age ± 2 years, and follow-up without recurrence equal to
or longer than the time to reconstruction of the respective
matched reconstructed patient were considered. In this
initial step, each case could have a number of candidate
controls of 0-X. A reference day was calculated for each of
the controls in these groups representing time from primary
surgery for the control plus time from primary surgery until
reconstruction for the matched case. Therefore, time from
primary surgery until reconstruction/reference day could
by calculated for cases and controls, respectively. A paired
control was randomly selected from this group. If this
group was empty, increased age interval up to 5 years was
allowed as a first step, and in a few cases when the age
difference was considered clinically relevant (e.g., pre- vs
postmenopausal), patients with similar, but not identical T
classification (e.g., T2 instead of T1) within the right age
interval were considered. This group of 312 patients, whose
characteristics are shown in Table 1, will be hereafter
labeled ‘‘matched control group.’’
Follow-up
Time to recurrence (TTR) was recorded as the time from
primary surgery to recurrence. The endpoint of primary
interest was the first evidence of recurrence: survival times
were calculated as the time elapsed since primary surgery
170 Breast Cancer Res Treat (2016) 158:169–178
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Breast reconstruction cohort n= 445 Control population from the Norwegian 
cancer registry n= 1341.
Matched control group
(no reconstruction) n= 312 





No cancer n= 1
Occurrence of other malignancies n= 4






Missing information n= 61
Control group = 868
Matching on T, N, age,  follow up free from 
recurrence1
Fig. 1 Inclusion and exclusion
criteria employed to achieve
case, control, and matched
control populations. DCIS
ductal carcinoma in situ, LCIS
lobular carcinoma in situ, BCT
breast-conserving therapy. 1
Recurrence-free follow-up time
equal to or longer than the time
to reconstruction of the
respective matched
reconstructed patient
Table 1 Patient, tumor, and treatment characteristics
Reconstruction
group n = 312 (%)
Control group
n = 868 (%)
Matched control
n = 312 (%)
Year of primary diagnosis
1977–1989 15 (4.8) 57 (6.6) 25 (8.0)
1990–1999 99 (31.7) 298 (34.3) 109 (34.9)
2000–2009 198 (63.5) 513 (59.1) 178 (57.1)
Median age at diagnosis 48.0 50.0 49.0
Mean age at diagnosis 48.1 50.7 48.7
Age\50 171 (54.8) 397 (45.7) 171 (54.8)
Age C50 141 (45.2) 471 (54.3) 141 (45.2)
Tumor size
T1 190 (60.9) 379 (43.7) 192 (61.5)
T2 91 (29.2) 332 (38.2) 94 (30.1)
T3 22 (7.1) 87 (10.0) 21 (6.7)
T4 2 (0.6) 43 (5.0) 2 (0.6)
Missing 7 (2.2) 27 (3.1) 3 (0.9)
Nodes
Negative 212 (67.9) 428 (49.3) 210 (67.3)
Positive 100 (32.1) 421 (48.5) 102 (32.7)
Missing 19 (2.2)
ER status
Negative 61 (19.6) 190 (21.9) 60 (19.2)
Positive 218 (69.9) 544 (62.7) 216 (69.2)
Missing 33 (10.6) 134 (15.4) 36 (11.5)
Adjuvant endocrine treatment
No 117 (37.5) 238 (27.4) 115 (36.9)
Yes 136 (43.6) 379 (43.7) 132 (42.3)
Missing 59 (18.9) 251 (28.9) 65 (20.8)
Adjuvant chemotherapy
No 144 (46.2) 327 (37.7) 136 (43.6)
Yes 143 (45.8) 305 (35.2) 125 (40.1)
Missing 25 (8.0) 235 (27.1) 51 (16.3)
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to recurrence or to the last documented follow-up with no
evidence of disease. Both locoregional recurrence and
distant metastasis were defined as the events of interest,
whereas all new primary tumors, including contralateral
breast cancers, were considered competing events, thus for
these patients survival times were censored at the time of
their occurrence. Adjuvant local and/or systemic treatment
was given according to national guidelines at the given
time period and was not affected by delayed breast
reconstruction. Follow-up after curative breast cancer
treatment in Norway does not include radiologic evaluation
or blood samples other than upon clinical suspicion of
distant metastases. Thus, diagnosis of relapse is most
commonly made after patients’ experience of symptoms.
Even when adopting more meticulous follow-up regimens,
more than 85 % of recurrences are detected following
symptomatic alert and not at controls [31]. Oncological
follow-up is not influenced by reconstructive surgery.
Statistical analysis
The event dynamics were studied by estimating with the
life-table method the hazard rate for recurrence, i.e., the
conditional probability of manifesting recurrence given
that the patient is clinically free from any recurrence at the
beginning of the interval. The probability of recurrence
over time, i.e., crude cumulative incidence (CCI), was
estimated according to a proper nonparametric estimator
adjusting for the presence of competing events and com-
pared by the Gray test [32]. A discretization of the time
axis in six-month units was applied and a Kernel-like
smoothing procedure [33] was adopted. For multivariable
regression analysis, the piecewise exponential model was
used. The piecewise exponential model provides a flexible
semiparametric tool in the study of the hazard function for
survival data, in the same fashion as a Cox regression
model [34]. The log-hazard function was modeled as an
additive function of the baseline log-hazard and the
covariate effects. For estimation of the piecewise expo-
nential model, the follow-up time was split into 3-month
disjoint intervals and the event rate was assumed to be
constant within each interval. The model accounts for
reconstruction as a time-dependent covariate (i.e., switch-
ing from 0 to 1 at the time it was performed). The model
was extended to account for the new timescale induced by
reconstructive surgery, namely the time elapsed since
reconstruction to the endpoint of interest [35]. For practical
purposes, time since reconstruction assumed the value 0,
before its occurrence, as well as for the controls.
Available prognostic factors were taken into account to
adjust the multivariable regression model. These included
age at diagnosis, pathologic tumor size (T2–T4 vs. T1),
nodal status (N? vs. N0), and estrogen receptor status
(ER? vs. ER-), with time-dependent effect (by introduc-
ing Time (since primary tumor surgery) * ER interaction).
To allow for the estimation of baseline hazard, both
timescales were modeled via Natural Splines with 5 knots
(corresponding to the quantiles of event times only). For
age at diagnosis, a possible nonlinear effect was also tested.
Statistical analyses were done using R3.02 software for
Windows, with Epi package added.
Results
Of the 312 patients, 302 had reconstructive surgery within
180 months and 291 within 120 months after primary
surgery, whereas the remaining 10 had longer time to
reconstruction. Median time to reconstruction was
33 months (range: 1–362 months). Median follow-up after
reconstruction was 137 months. Within 10 years after pri-
mary surgery, 39 of the 312 reconstructed patients devel-
oped local (5), regional (6), or distant (31) relapse,
compared to 52 patients in the matched control group (local
10, regional 3, distant 39).
As a first step, the recurrence dynamics for the recon-
structed patients were analyzed with the time origin at
primary cancer surgery (Fig. 2, blue line). As expected, a
bimodal hazard rate pattern was observed, with an early
less prominent peak in comparison with the second later
one. When the recurrence dynamics were analyzed with
reconstructive surgery as the time origin, a distinct early
peak in recurrences was found around 18 months postre-
construction, followed by a second lower peak at the 5th–
6th year (Fig. 2, red line). The height of this peak was
dependent on the extent of surgery. More extensive surg-





















Recurrence post reconstruction 
t=0 at Reconstruction
t=0 at Surgery
Fig. 2 Recurrence pattern for the reconstructed patients (n = 312)
with T = 0 set at reconstruction (red line) and at primary surgery
(blue line). X-axis represents time in months. Y-axis represents six-
month hazard rate
172 Breast Cancer Res Treat (2016) 158:169–178
123
transverse rectus abdominis myocutaneous (TRAM) flaps,
and combined implant and flap surgery as compared with
simple implant resulted in a higher peak for the former
(Fig. 3). The timing of the peak was not affected by the
extent of surgery. There was no difference in recurrence-
free survival between extensive reconstructive surgery and
simple implant surgery (Fig. 4, Gray test, p = 0.86).
Similarly, the height of the recurrence peaks, but not the
timing, was dependent on known risk factors such as nodal
involvement and T stage (Fig. 5).
The relapse pattern for the matched control group, when
the time origin was set at mastectomy, followed the
expected bimodal pattern with a first, dominant early peak
and a second less marked peak at 5 years after primary
surgery (Fig. 6), as frequently demonstrated in previous
studies. When the time origin was moved to the reference
day, the hazard rate curve appears as a simple distortion of
the previous one (figure not reported). Unlike the recon-
structed patients, no definite trait was detectable. The
recurrence incidence was slightly reduced for the recon-
structed patients in comparison with matched control
patients, although the difference was not statistically sig-
nificant (Fig. 7, Gray test, p = 0.08).
The multiple scale analysis supports the hypothesis of a
transitory significant increase of recurrence risk during the
first two years after reconstruction/reference day for
reconstructed patients in comparison with the not recon-
structed patients. In the multivariable regression model,
where all 868 patients in the control group were analyzed,
all factors that were considered confirmed their expected
prognostic impact, including the time-dependent effect of
ER status, whereas age at diagnosis did not. The hazard
ratio (HR) was higher in node-positive patients and in those
with increasing tumor size (Table 2). The multiple time-
scale model allows for understanding whether the time
effect, induced by reconstruction occurrence, may be rel-
evant for the subsequent risk of developing unfavorable
events. To better interpret the model, a graph showing the
effect of the timescale induced by reconstruction surgery is
shown in Fig. 8. The figure shows how the hazard ratio for
recurrence between reconstructed patients and control
patients (with the same clinical and pathological features
and with the same follow-up time since primary tumor
surgery) may not be considered constant during the sub-
sequent follow-up time. Although not fully significant with
a moderately wide confidence interval, it shows an
increased risk for the reconstructed patients within the first
2 years, with a peak at about 18 months after surgery and
decreasing thereafter. Of note, the recurrence dynamics
following reconstructive surgery were unaffected by the
time from primary surgery to reconstruction, both in timing
and magnitude.
Discussion
To our knowledge, this is the first study investigating the
dynamics of recurrences occurring after delayed breast
reconstruction in breast cancer patients. The main result of
our analysis is that when the time origin is set at the
reconstruction date, the hazard rate for ensuing recurrence
displays a first main peak in the 2nd year and a later minor
peak at the 5th–6th year after reconstruction (Fig. 2, red
line). The recurrence risk for the same patients, when the
time origin is placed at mastectomy, is bimodal with peak
positions at the same time points relative to mastectomy,
after 2 and 5–6 years (Fig. 2, blue line), as expected [31].
Thus, when the time origin is moved for each reconstructed
patient to the reconstruction date, the recurrence risk pat-
tern is similar to that observed following primary mastec-
tomy. Of note, time origin displacement reveals an increase
of the early peak with a concomitant decrease of the late
level of recurrence risk (Fig. 2), suggesting that recurrence
redistribution is associated with the reconstruction
maneuver which could be said to act as a wave breaker for
recurrences. These findings suggest that mastectomy and
reconstruction induce similar biological effects on sub-
clinical preexisting metastases.
The effects of primary mastectomy have been investi-
gated in both animals and humans during the past century
[36]. An unintentional effect of surgery in breast cancer
patients with clinically undetectable micrometastatic dis-
ease has been explained by a paradigm based on the con-





















Recurrence post reconstruction 
Unilateral implant
DIEP / TRAM / Bilateral procedures
Fig. 3 Recurrence pattern according to surgical intervention demon-
strates an enhanced, but similarly timed, effect by increased extent of
trauma. Blue line patients receiving a unilateral implant. Red line
patients receiving more extensive surgery. X-axis represents time in
months since reconstructive surgery. Y-axis represents six-month
hazard rate. DIEP deep inferior epigastric perforator, TRAM trans-
verse rectus abdominis myocutaneous flap
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related enhancement of metastasis growth [37]. The model
assumes both cellular and micrometastatic tumor dor-
mancy, with ordered transitions between these two quies-
cent states and subsequent development of overt metastasis
and, subsequently, a transient phase of acceleration of
metastatic growth. Preclinical studies have pointed to an
angiogenic switch as a possible involved mechanism, in
which the microenvironment is altered by tissue trauma to
become proangiogenic with increased levels of VEGF and
reduced levels of angiogenesis inhibitors such as TSP-1
[8]. Others have focused on the role of surgery-induced
immunomodulation with demonstration of a stimulatory
interaction between cells of the innate immune system and
adjacent cancer cells [38]. The truth may lie in both models
as the immune and angiogenic systems have multiple
points of intersection [39]. Our findings support the con-
cept that also delayed breast reconstruction may accelerate
metastatic growth in subjects with dormant metastatic foci
similar to the effects observed after primary surgery. This
explanation is further supported by the finding that surgical
approaches with different extents result in different recur-
rence risks, although with the same time rhythm (Fig. 3).
Specifically, the more extensive reconstruction modalities
DIEP/TRAM and bilateral surgical procedures give rise to
a higher early peak in comparison with unilateral implant
surgery. This difference is limited to the recurrence risk
level, which is differently modulated within the same time
cadence, while the two types of reconstruction do not affect
long-term outcome differently (Fig. 4).
The proposed explanation assumes that the risk of
clinical appearance of metastasis is dependent on the action
of surgery-related factors on the subclinical metastatic state
of the host. This assumption is confirmed by the marked
influence of both tumor size and nodal status on the hazard
Fig. 4 The probability of
recurrence over time, i.e., Crude
Cumulative Incidence (CCI),
was estimated according to
proper nonparametric estimator
adjusting for the presence of
competing events and was
compared between groups by
the Gray test. Simple unilateral
implant (black line) and more
extensive surgery such as DIEP/
TRAM or bilateral procedures
(red line). X-axis represents
time since reconstruction in
months. There is no observable
















































Fig. 5 Subgroup analysis of recurrence pattern by known prognostic
factors. Increasing T and N stages are associated with an enhancing
effect on preexisting recurrence risk. Left figure demonstrates the
recurrence dynamics for node-positive (red line) and node-negative
(blue line) reconstructed patients. Right figure demonstrates the
recurrence dynamics for reconstructed patients with tumors [2 cm
(red line) and B2 cm (blue line). X-axis represents months since
reconstruction. Y-axis represents six-month hazard rate
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level (Fig. 5). At diagnosis, these two well-known prog-
nostic factors indicate the recurrence risk during the dis-
ease course. Thus, it is coherent that an additional
triggering factor, such as delayed surgical reconstruction,
may result in different outcomes when patients with dif-
ferent underlying recurrence risk are involved.
When studying the relation between outcomes of
patients undergoing delayed reconstruction in comparison
with patients undergoing mastectomy without reconstruc-
tion, crucial problems emerge. In addition to the retro-
spective nature of such studies, the reconstructed group is
characterized by a selection event not yet occurred (and
therefore unknown) at the mastectomy time and, moreover,
occurring at varying patient-related times during follow-up,
thus raising important issues in the statistical analysis. To
overcome these drawbacks, we used two different
approaches. In the first approach, which has been fre-
quently adopted in this field in spite of its intrinsic naivety
[28, 29], we performed a matched random choice of the
control patients. For each reconstructed patient, we ran-
domly identified a matched control patient with similar
initial characteristics, selecting her among the not recon-
structed patients who were disease free at the date of
reconstruction of the considered patient. This matching
modality resulted in a good balance between the two sets of
patients (Table 1) and avoided drawbacks detectable in
published reports, such as dissimilar patient characteristics




















Recurrence (t=0 at  primary surgery) 
Reconstructed patients
Matched controls
Fig. 6 Recurrence pattern for the reconstructed patients and the
matched control patients with T = 0 at primary surgery. Red line
reconstructed patients. Blue line control patients. X-axis represents
months since primary surgery. Y-axis represents six-month hazard
rate
Fig. 7 The probability of recurrence over time, i.e., Crude Cumula-
tive Incidence (CCI), was estimated according to proper nonpara-
metric estimator adjusting for the presence of competing events and
was compared between groups by the Gray test. Red line recon-
structed patients. Blue line matched control patients. Despite match-
ing by age, time of diagnosis, and T and N stage, there is a
nonsignificant trend for a more favorable prognosis in the recon-
structed patients. X-axis represents time in months since reconstruc-
tion/reference day (see m&m) for reconstructed patients and control
patients, respectively. Y-axis represents accumulated recurrence-free
survival
Table 2 Hazard ratio for recurrence according to tumor
characteristics
HR 95 % CI
ER pos versus neg (18 months) 0.30 0.19 0.47
ER pos versus neg (60 months) 1.77 0.81 3.86
T2 versus T1 1.91 1.43 2.56
T3 versus T1 2.78 1.89 4.09
T4 versus T1 3.13 1.91 5.11
N? versus N- 1.98 1.52 2.59
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addition, the recurrence dynamics of matched controls,
when time origin was set at mastectomy (Fig. 6, blue line),
was coherent with the analogous hazard rate pattern
observable in similar patients from different databases [31].
It displays a first peak significantly higher than the corre-
sponding peak of reconstructed patients (Fig. 6, red line)
revealing that, in spite of the balanced initial prognostic
factors, matched control patients display worse prognosis
than reconstructed patients. This finding is consistent with
a population-based registry study analyzing Danish women
who received reconstruction with implants only [41].
In the second approach, we addressed the analysis in the
framework of multiple timescales in multistate models [35].
The regression analysis involved all 868 control patients
and 312 reconstructed patients. It accounted for the joint
effect of prognostic factors (e.g., tumor size, nodal status,
etc.) and, most importantly, the change in the hazard rate for
recurrence resulting from specific events, such as recon-
struction, occurring at varying time points. The multiple
scale analysis provides evidence that following recon-
struction women suffer a transitory, significant increase of
recurrence risk during the first 2 years in comparison with
not reconstructed patients (Fig. 8). This finding provides
structural evidence for the enhancing effect of reconstruc-
tive surgery on subclinical metastases, which brings on the
temporary raise of clinically evident recurrences. Such
behavior is suggestive when it is considered in the light of
the above-reported model. Indeed, the whole pattern would
suggest that the early peak may be caused by an event that
has been brought forward, and in the absence of recon-
struction were to be expected at a later time. Taken together,
the two analysis approaches provide evidence that recon-
structed patients (a) suffer increased surgery-related recur-
rence rate following the usual bimodal pattern and
(b) display disease-free survival that is not worse (maybe
even better) than that of not reconstructed patients (Fig. 8).
Although not directly comparable, the recurrence pat-
tern analysis apparently diverges somewhat from a previ-
ous investigation where trauma or intervening surgical
procedures unrelated to cancer were not associated with an
increased rate of breast cancer recurrence [42]. Still, the
fact that the effect of delayed reconstruction on the
recurrence dynamics does not translate into reduced
recurrence-free or overall survival is in keeping with most
reports on the same subject [28, 29, 40, 41, 43]. The reason
underlying the similar or relatively better long-term out-
come of reconstructed patients is presently undetermined.
Patients opting for reconstruction tend to be younger and
have less comorbidity. Most studies to date have focused
on immediate reconstruction [43–45]. We are inclined to
ascribe this finding to selection bias of patients receiving
reconstruction due to factors here unaccounted for, such as
socioeconomic conditions and better general health. The
former factor is related to the finding that patients who are
of lower socioeconomic status are more likely to have a
recurrence than women of higher social class [46].
Fig. 8 Multiple timescale analysis of the hazard ratio for recurrence
between the reconstructed patients and the controls in relation to time
since reconstruction. Dotted lines represent 95 % CI. X-axis
represents months since reconstruction/reference day. Y-axis repre-
sents the ratio between the six-month hazard for recurrence between
reconstructed patients and controls
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Furthermore, current smokers or diabetic patients are not
accepted for microvascular free (DIEP) or pedicle flap
surgery (TRAM). In addition, body mass index, which is a
prognostic factor in cancer [47, 48], would not be higher
than 30 in patients offered advanced reconstruction. Most
patients undergoing DIEP or TRAM procedures have a
secondary or even tertiary surgery performed due to cos-
metic purposes or complications. Thus, the observations
are measurements of the effect from the first extensive
reconstructive surgical procedure, independent of the
duration of reconstructive surgery or the number of surgi-
cal events. Again, such subsequent procedures might rep-
resent a possible bias and the observed effects might
therefore be diluted.
In conclusion, our study indicates that reconstructive
breast cancer surgery constitutes an independent stimulat-
ing event on the growth of micrometastases leading to
accelerated relapse rates. The effect is similar to that
observed after primary breast cancer surgery. Importantly,
this does not translate into worse long-term disease-free
survival. Our results may provide indirect evidence that
immediate reconstruction would be more beneficial than
delayed as this obviates one possible growth stimulating
event. Still, randomized trials assessing this question are
not ethically or practically feasible. Further studies are
ongoing and will shed more light on tumor biological
mechanisms behind the observed phenomenon.
Acknowledgments This work was partly supported by the University
of Bergen and the Research Council of Norway through its Centres of
Excellence funding scheme, project number 223250, and by grants
from the Helse Vest Research Fund, The Italian Association for
Cancer Research, and the Norwegian Cancer Society.
Compliance with ethical standards
Conflict of interest The authors declare no conflict of interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Brewster AM, Hortobagyi G, Broglio KR, Kau SW, Santa-Maria
CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M,
Esteva FJ (2008) Residual risk of breast cancer recurrence
5 years after adjuvant therapy. J Natl Cancer Inst 100(116):
1179–1183
2. Fisher B (1980) Laboratory and clinical research in breast cancer:
a personal adventure: the David A Karnofsky memorial lecture.
Cancer Res 40:3863–3874
3. Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti
M, Bonadonna G (1994) Local recurrences following mastec-
tomy: support for the concept of tumor dormancy. J Natl Cancer
Inst 86(1):45–48
4. Luzzi KJMI, Schmidt EE, Kerkvliet N, Morric VL, Chambers
AF, Groom AC (1998) Multistep nature of metastatic ineffi-
ciency: dormancy of solitary cells after successful extravasation
and limited survival of early micrometastases. Am J Pathol
153:865–873
5. Ghajar CMPH, Mori H, Matei IR, Evason KJ, Brazier H, Almeida
D, Koller A, Hajjar KA, Stainier DYR, Chen EI, Lyden D, Bissell
MJ (2013) The perivascular niche regulates breast tumour dor-
mancy. Nat Cell Biol 15(7):807–817. doi:10.1038/ncb2767
6. Klauber-DeMore NVZ, LinkovI KJ, Brogen PI, Gerald WL
(2001) Biological behavior of human breast cancer micrometas-
tases. Clin Cancer Res 7:2434–2439
7. Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evi-
dence for cancer dormancy. Nat Rev Cancer 7:834–846
8. Naumov GAL, Folkman J (2006) Role of angiogenesis in human
tumor dormancy: animal models of the angiogenic switch. Cell
Cycle 5(16):1779–1787
9. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ,
Smyth MJ, Schreiber RD (2007) Adaptive immunity maintains
occult cancer in an equilibrium state. Nature 450(7171):7903–
7907
10. Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, de
Stanchina E, Massague J (2016) Metastatic latency and immune
evasion through autocrine inhibition of WNT. Cell 165(1):45–60.
doi:10.1016/j.cell.2016.02.025
11. Ranganathan AC, Adam A, Aguirre-Ghiso JA (2006) Opposing
roles of mitogenic and stress signaling pathways in the induction
of cancer dormancy. Cell Cycle 5(16):1799–1807
12. Sosa MSBP, Debnath J, Aguirre-Ghiso JA (2013) Regulation of
tumor cell dormancy by tissue microenvironments and autop-
hagy. Adv Exp Med Biol 734:773–789
13. Hanin LB-MS (2014) Reconstruction of the natural history of
metastatic cancer and assessment of the effects of surgery:
Gompertzian growth of the primary tumor. Math Biosci 247:
248–257
14. Demicheli RFM, Ambrogi F, Hiigins K, Boyd JA, Biganzoli E,
Kelsey CR (2012) Recurrence dynamics for non-small-cell lung
cancer, effect of surgery on the development of metastases.
J Thorac Oncol 7:723–730
15. Kelsey CRFM, Ambrogi F, Higgins K, Boyd JA, Biganzoli E,
Demicheli R (2013) Metastasis dynamics for non-small-cell lung
cancer: effect of patient and tumor-related factors. Clin Lung
Cancer 14(4):425–432
16. Fisher BGN, Saffer EA (1983) Influence of the interval between
primary tumor removal and chemotherapy on kinetics and growth
of metastases. Cancer Res 43:1488–1492
17. Peeters CF, Wobbes dWR T, Westphal JR, Ruers TJ (2006)
Outgrowth of human liver metastases after resection of the pri-
mary colorectal tumor: a shift in the balance between apoptosis
and proliferation. Int J Cancer 119(6):1249–1253
18. Curigliano GPJ, Bertolini F, Colleoni M, Peruzzotti G, de Braud
F, Gandini S, Girlado A, Martella S, Orlando L, Munzone E,
Pietri E, Luini A, Goldhirsch A (2005) Systemic effects of sur-
gery: quantitative analysis of circulating basic fibroblast growth
factor (bFGF), vascular endothelial growth factor (VEGF) and
transforming growth factor beta (TGF-b) in patients with breast
cancer who underwent limited or extended surgery. Breast Can-
cer Res Treat 93:35–40
19. Shao LOT, Sakamoo M, Mori S, Kodama T (2015) Activation of
latent metastases in the lung after resection of a metastatic lymph
node in a lymph node metastasis mouse model. Biochem Biophys
Res Comm 460:543–548
Breast Cancer Res Treat (2016) 158:169–178 177
123
20. Dillekas H, Transeth M, Pilskog M, Assmus J, Straume O (2014)
Differences in metastatic patterns in relation to time between
primary surgery and first relapse from breast cancer suggest
synchronized growth of dormant micrometastases. Breast Cancer
Res Treat 146(143):627–736
21. Retsky MW, Demicheli R, Hrushesky WJ, Baum M, Gukas ID
(2008) Dormancy and surgery-driven escape from dormancy help
explain some clinical features of breast cancer. APMIS
116(117–118):730–741
22. Lee JW, Shahzad M, Lin YG, Armaiz-Pena G, Mangala LS, Han
HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone
RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK
(2009) Surgical stress promotes tumor growth in ovarian carci-
noma. Clin Cancer Res 15(18):2695–2702
23. Oosterling SJ, Van der Bij G, van Egmond M, van der Sijp JR
(2005) Surgical trauma and peritoneal recurrence of colorectal
carcinoma. Eur J Surg Oncol 31(31):29–37
24. Morihara K, Takenaka H, Morihara T, Kishimoto S (2007) Pri-
mary cutaneous anaplastic large cell lymphoma associated with
vascular endothelial growth factor arising from a burn scar. J Am
Acad Dermatol 57(55):S103–S105
25. Retsky M, Demicheli R, Hrushesky W, Baum M, Gukas I (2010)
Surgery triggers outgrowth of latent distant disease in breast
cancer: an inconvenient truth? Cancers (Basel) 30(32):305–337
26. Demicheli RRM, Swartzendruber DE, Bonadonna G (1997)
Proposal for a new model of breast cancer metastatic develop-
ment. Ann Oncol 8(11):1075–1080
27. Retsky MWDR, Swartzendruber DE, Bame PD, Wardwell RH,
Bonadonna G, Speer JF, Valagussa P (1997) Computer simula-
tion of a breast cancer metastasis model. Breast Cancer Res Treat
15(2):193–202
28. Isern AE, Manjer J, Malina J, Loman N, Mårtensson T, Bofin A,
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29. Hölmich LRDM, Foged Henriksen T, Krag C, Brix Tange U,
Kjøller K, McLaughlin JK, Olsen JH, Friis S (2008) Delayed
breast reconstruction with implants after invasive breast cancer
does not impair prognosis. Ann Plast Surg 61:11–18
30. Registry TNC (2014) Nasjonalt kvalitetesregister for brystkreft-
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Abstract
Background: The aim of the research was to separate the distant metastasis (DM) enhancing effect due to breast
tumour removal from that due to surgical manoeuvre by itself.
Methods: DM dynamics following surgery for ipsilateral breast tumour recurrence (IBTR), contralateral breast cancer
(CBC) and delayed reconstruction (REC), which was performed after the original breast cancer surgical removal, was
analysed. A total of 338 patients with IBTR, 239 with CBC and 312 with REC were studied.
Results: The DM dynamics following IBTR, CBC and REC, when assessed with time origin at their surgical treatment,
is similar to the analogous pattern following primary tumour removal, with a first major peak at about 18 months
and a second lower one at about 5 years from surgery. The time span between primary tumour removal and the
second surgery is influential on DM risk levels for IBTR and CBC patients, not for REC patients.
Conclusions: The role of breast tumour removal is different from the role of surgery by itself. Our findings suggest
that the major effect of reconstructive surgery is microscopic metastasis acceleration, while breast tumour surgical
removal (either primary or IBTR or CBC) involves both tumour homeostasis interruption and microscopic metastasis
growth acceleration. The removal of a breast tumour would eliminate its homeostatic restrains on metastatic foci,
thus allowing metastasis development, which, in turn, would be supported by the forwarding action of the
mechanisms triggered by the surgical wounding.
Keywords: Breast cancer, Recurrence dynamics, Metastasis development, Second surgery, Tumour homeostasis,
Surgery-related metastasis acceleration
Background
In the middle of the nineteenth century, the arguments
set out by Virchow, who suggested that the disease starts
as a single focus within the breast, then migrates to the
axillary lymph nodes and ultimately to distant organs,
supported the Halsted operation that was adopted as the
default therapy worldwide [1]. However, among resected
patients, 30% of node-negative and 75% of node-positive
women still developed distant metastases and succumbed
[2]. The failure of mastectomy and other more aggressive
operations to cure patients and, moreover, novel
biology-based assumptions on the disease course [3] sug-
gesting that the extent of local treatment does not affect
survival supported a reduction of the extent of surgery.
Additionally, clinical investigations and mathematical
modelling advocated that surgical resection might not al-
ways be beneficial [4, 5] providing evidence that, while it
favourably modifies the natural history of breast cancer
for the majority of patients, it may also hasten the meta-
static development for a number of them, by triggering
growth of occult tumour deposits. The concepts under-
lying this new model extended to the clinical level the re-
sults of a protracted history of investigations lasting more
than a century [6].
Helpful hints about the new model were achieved
from analyses of post-resection recurrence dynamics in
early breast cancer patients undergoing potentially
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curative removal of the primary tumour [7, 8]. A model
assuming post-surgery acceleration of disease progres-
sion by a burst of growth in previously dormant micro-
metastases appeared to best fit the clinical data. Similar
findings were observed in non-small cell lung cancer [9].
While this acceleration apparently occurs at the time of
local treatment, it is still not deciphered whether this ef-
fect can be ascribed to primary tumour removal (e.g. to
removal of inhibitory factors) or to the surgical
manoeuvre per se (e.g. CTC release, immune suppres-
sion and pro-angiogenic stimulus of wounding) or to
both. This differentiation is important as it may open a
window to new therapeutic approaches.
Clues about this subject may be detected by the ana-
lysis of the recurrence dynamics in patients who
undergo subsequent breast surgical manoeuvres during
the follow-up of the disease in addition to primary
tumour surgical removal. Patients undergoing conserva-
tive surgery for their primary tumour may experience ip-
silateral breast tumour recurrence (IBTR), and others
may be diagnosed contralateral breast cancer (CBC)
whatever the surgical approach for the primary tumour
has been. Moreover, some patients undergoing mastec-
tomy as the first surgical treatment call for breast recon-
struction (REC) and undergo aesthetical surgery. We
hypothesized different metastatic recurrence dynamics
associated with the different surgical procedures due to
the clinical presence (IBTR and CBC) or absence (REC)
of a tumour reservoir in the breast. Therefore, we report
here findings from the analysis of distant metastasis
(DM) dynamics following IBTR, CBC and REC, which
was carried out with the aim of unravelling the different
roles, if any, of the two possible factors, i.e. breast
tumour removal and surgical manoeuvre by itself.
Patients and methods
At the National Cancer Institute of Milan, three ran-
domized clinical trials have been carried out in the past,
investigating the role of different surgical approaches for
primary tumour removal. Moreover, since preliminary
results of the first trial on the breast-conserving treat-
ment for early breast cancer, which provided evidence
that conservative surgery plus chest wall radiotherapy
was comparable to more aggressive resections [10], pa-
tients received breast-conserving treatment as routine
practice outside randomized clinical trials (out-trial
patients). All axillary node-positive (N+) patients were
offered systemic adjuvant treatment with cyclophospha-
mide + methotrexate + fluorouracil (CMF) or CMF plus
doxorubicin, while no further post-surgical systemic
treatment was recommended to axillary node-negative
(N−) patients. Adjuvant hormone therapy was not uti-
lized within the randomized clinical trials and seldom
employed for out-trial patients, as it was not considered
mandatory at that time. Two other randomized clinical
trials were accomplished on patients who, following
mastectomy or breast-conserving treatment, were found
to be axillary node positive (N+). Patients with one to
three positive axillary lymph nodes were randomly allo-
cated to receive either 12 courses of CMF or 8 courses
of the same regimen followed by 4 courses of doxorubi-
cin, while patients with > 3 positive axillary nodes were
randomized to receive either four courses of doxorubicin
followed by 8 courses of CMF or 2 courses of CMF and
1 course of doxorubicin for a total of 12 courses. All
clinical data from patients enrolled into the reported
clinical trials or treated outside of trials were systematic-
ally recorded and stored in standard format. Detailed de-
scriptions of patients, treatments and follow-up
modalities have been reported elsewhere [10–14]. In par-
ticular, data for patients suffering IBTR are reported in
ref. [15].
A further database was analysed, including all breast
cancer patients undergoing mastectomy who underwent
delayed reconstructive surgery at Haukeland University
Hospital, Bergen, Norway. The reconstructive proce-
dures were implant surgery, implants combined with
flaps, deep inferior epigastric perforator flaps and trans-
verse rectus abdominis myo-cutaneous flaps. A paired
control was randomly selected from patients with identi-
cal T and N stages, age ± 2 years, and follow-up without
recurrence equal to or longer than the time to recon-
struction of the respective matched reconstructed pa-
tient (defined as “reference time”, i.e. the time origin for
the analysis of DM dynamics for controls). Patient char-
acteristics and details of the study have been reported in
ref. [16]. All studies supplying the analysed databases
were approved by the institutional ethics committees
and review boards in accordance with the Declaration of
Helsinki.
The analysis of recurrence dynamics was focused on
DM as the first event after the second surgery (the
studied timing periods are outlined in Fig. 1): DM-free
survival times were calculated as time elapsed since the
second surgery (for IBTR, CBC or REC) to DM occur-
rence or to the last documented follow-up with no evi-
dence of disease. Second primary tumours, including
contralateral breast cancers, were considered as com-
peting events, and the corresponding event-free
survival times were censored at the time of their occur-
rence. The DM dynamics was studied by estimating
with the life-table method the hazard rate for DM, i.e.
the conditional probability of manifesting DM during a
certain time span, given that the patient is clinically
DM free at the beginning of the interval [17]. A
discretization of the time axis in 6-month units was ap-
plied, and a Kernel-like smoothing procedure [18] was
adopted.
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Results
A CONSORT diagram for IBTR, CBC and REC patients
and matched controls is reported in Fig. 2.
Among patients undergoing conservative surgery, 92%
received chest wall radiation therapy, mostly at the total
dose of 50 Gy (daily dose 2 Gy) with high energy plus 10
Gy (daily dose 2 Gy) as a boost with orthovoltage to the
ipsilateral breast. Following the diagnosis of IBTR or
CBC, the treatment was decided on an individual basis.
Median follow-up times after IBTR and after CBC were
151 months and 144 months, respectively. The number
of patients suffering DM diagnosis within 10 years from
IBTR and CBC was 138 and 84, respectively.
In the Norwegian study, the matched control group in-
cluded patients who were extracted from a total of 868 (see
the “Patients and Methods” section in ref. [16]). Median
follow-up after reconstruction or reference time for con-
trols was 137months. The number of patients suffering
DM within 10 years for REC and controls was 44 and 45,
respectively.
Main patient characteristics at primary tumour treat-
ment are reported in Table 1. In spite of the wide time
span of patient accrual, the homogeneity of main prog-
nostic factors across the databases, with the exception of
tumour size in REC patients, is noteworthy. Axillary
node involvement is near identical, as well as the fre-
quency of ER-positive and ER-negative tumours among
assessed ones, despite the fact that ER content was mea-
sured at different frequencies in the three series. Any-
way, the DM dynamics of ER+ and ER− cancer have
similar timing pattern [19] and, therefore, no modifica-
tion of surgery effects on the time patterns was expected
by oestrogen receptor levels. Moreover, as analysed pa-
tients suffering IBTR and CBC did not receive adjuvant
endocrine therapy just like 42% of ER+ reconstructed
patients, the question of whether endocrine therapy may
alter DM patterns in a modern cohort remains open.
HER2 status was not available and, accordingly, no spe-
cific treatment was administered.
The distribution of surgical treatments for IBTR, CBC
or REC during the follow-up subsequent to primary
tumour removal is reported in Fig. 3. Reconstructions
were performed mainly during the first 5 years (median
time 2.5 years) while IBTR removal had a more pro-
tracted distribution (median time 4.3 years) and a struc-
tured pattern [20]. CBC treatments have a steadier
pattern consistent with the notion that the occurrence
of a CBC may be considered a random event not
time-related with primary tumour [21, 22].
The DM dynamics was analysed for the four groups
in a timeframe with t = 0 at second surgery (Figs. 4
and 5 solid lines). Moreover, the influence of the time
elapsed from primary tumour removal to the second
surgical manoeuvre [time to second surgery] on the
hazard rate for DM pattern was investigated as well
(Figs. 4 and 5 dashed lines). The hazard rate pattern is
similar for the three surgical groups with a first major
peak at about 18 months and a second lower one at
about 5 years from the second surgery, although the
three levels of recurrence risk are different. Time to
second surgery is apparently not influential for recon-
structed patients, whereas it changes the first peak
height for the other sets, showing that the influence is
maximal for early re-operations, decreases afterwards
and apparently disappears for time to second surgery
values larger than 2 to 3 years. To ascertain whether
factors known to be influent on the risk level may
drive the described phenomenon, we analysed the
DM dynamics by time to second surgery in IBTR pa-
tients pooled by axillary node status (node positive vs
node negative) and by second surgery extent (mastec-
tomy vs conservative surgery). In all analysed subsets,
the time to second surgery aroused the same hazard
rate pattern, as Fig. 5 exemplifies for the axillary
nodal involvement. A comparison between REC pa-
tients and controls for DM hazard rate pattern is re-
ported in Fig. 6, where the accelerating effect of
surgery on the DM dynamics is quite evident.
Fig. 1 Analysed times: time to second surgery (from primary cancer surgery to surgery for ipsilateral breast tumour recurrence (IBTR), contralateral
breast cancer (CBC) or breast reconstruction (REC)) and time to distant metastasis (from the second surgery to the appearance of distant metastasis)
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Discussion
Our analysis on breast cancer patients undergoing breast
surgery for IBTR, CBC and REC provides two main re-
sults: (1) the DM dynamics following a new breast surgi-
cal manoeuvre performed after primary tumour removal
is similar to the analogous dynamics following primary
tumour removal and (2) the time span between the two
operations is not associated with changes in peak timing;
yet, for IBTR and CBC patients, it is related to progres-
sive reduction of DM risk levels, while REC patients dis-
play similar DM risk levels for all time spans.
It should be emphasized that the three surgeries are per-
formed in different clinical situations. Surgery for IBTR is
strictly related to the specific multimodal dynamics of
IBTR appearance [15] while CBC diagnosis and
subsequent removal is an independent event with steady
hazard rate [21, 22] and, finally, REC surgery is related to
the patient’s desire and only indirectly to clinical condi-
tions. Therefore, when comparative analyses among pa-
tients with such different tumour-host settings at the time
of surgery display similar behaviours, they are reasonably
attributable to the act of treatment per se. Our findings
suggest that there is a metastasis-enhancing effect in all
surgical interventions, which displays, however, different
traits related to whether a macroscopic breast tumour is
removed or not.
The enhancing effect of surgical primary tumour re-
moval on metastatic disease is well supported by a long
history of investigations [6] and from a few clinical stud-
ies in humans (e.g. [23]). It enables to explain the
Fig. 2 A CONSORT diagram for IBTR, CBC, REC and control patients. Analysed data were from trials carried out between 1975 and 1990 (IBTR,
CBC) and between 1977 and 2007 (REC, controls)
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multipeak pattern of the hazard rate for recurrence in
patients with early breast cancer undergoing surgery or
surgery plus adjuvant chemotherapy [7]. Here, we con-
firm that this enhancing effect is observable even when
surgical manoeuvres are performed in the breast area at
a later date. The result of our analysis apparently
diverges from the outcome of a previous investigation
on the same subject [24] suggesting that traumas or
intervening surgical procedures unrelated to cancer are
not associated with an increased cumulative rate of
breast cancer recurrence in a 2-year window. Although
this discrepancy may be related to the shortness of the
Table 1 Patient characteristics
IBTR (338) CBC (239) Rec (312) Controls (312)
Median age at diagnosis (years) 45 48 48 49
25%–75% 39–52 42–56 42–53 43–53
Range 21–69 22–75 29–73 28–71
Tumour size (%)
T1 85 84 61 62
T2 12 15 29 30
T3/4 – – 8 7
Missing 3 1 2 1
Node negative (%) 70 64 68 67
Node positive (%) 30 36 32 33
ER negative (%) 16 16 20 19
ER positive (%) 63 53 70 70
ER missing (%) 21 31 10 11
Fig. 3 Distribution of surgical treatments for IBTR (red line), CBC (fuchsia line) and reconstruction (blue line) during the follow-up with t = 0 at
primary tumour removal. RECs were performed mainly during the first 5 years (median time 2.5 years) while IBTR removal had a more protracted
distribution (median time 4.3 years) and CBCs had a steadier pattern consistent with the notion that the occurrence of a CBC may be considered
a random event
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analysed interval, a subtler inference could be consid-
ered on the basis of the known topological specificity of
cell populations [25, 26] and of the finding that, in an
animal model, acceleration in tumour growth by
mobilization of bone marrow-derived cells may be dif-
ferent after operative injuries to different organs [27]. In-
deed, one could speculate that surgery in the breast area
may stimulate distant breast cancer foci, unlike surgery
in other sites. Unfortunately, this hypothesis cannot be
disentangled since data on non-breast interventions
were not available for comparison.
Of note, the hazard rate peaks, in particular the first
one, have different heights in IBTR, CBC and REC (Fig. 4).
This occurrence is in keeping with the notion that the
sudden acceleration of metastasis development takes ac-
tion on the underlying DM dynamics, which is different in
IBTR, CBC and REC patients. Indeed, patients with IBTR
have an intrinsic high risk of DM (similar to N+ patients)
that was unpredictable by the usual prognostic factors at
the initial treatment and that is revealed when IBTR
emerges in advance of the competing DM events [15, 28].
In comparison with these patients, women suffering CBC
display a considerably lower first hazard rate peak (about
60% peak to peak) in keeping with the concept that CBC
is a second primary, unrelated to the first one [21, 29, 30].
Accordingly, patients with CBC actually fit to a population
with “average” DM risk [31]. Finally, patients undergoing
REC have better prognosis due to favourable selection cri-
teria: they had no previous recurrence event and factors
such as smoking, obesity and diabetes excluded patients
from being offered complex breast reconstructive proce-
dures. Moreover, the baseline risk in this population may
be influenced by features here not accounted for, such as
socioeconomic conditions, better general health and low
body mass index, which is recently emerging as a prog-
nostic factor in breast cancer [32].
Fig. 4 Distant metastasis dynamics following surgery for IBTR, contralateral breast tumour and reconstruction (t = 0 at second surgery). The hazard
rate pattern is similar for the three groups with a first major peak at about 24 months and a second lower one at about 5 years. The analysis was
performed for all patients (bold lines) and, moreover, by time from primary tumour removal to second surgery as well (dashed lines). While this
factor is not influent for reconstructed patients, it changes the first peak height for surgeries removing neoplastic nodules if the time to second
surgery is less than about 3 years. Confidence intervals on the estimated hazard rates at the first peak position are reported for all patients and
those with time to second surgery more than 48. Y-axis reports hazard rates for DM, i.e. the conditional probability of manifesting DM during an
interval of 6 months, given that the patient is clinically DM free at the beginning of the interval. X-axis units are months between primary tumour
removal and the second surgical manoeuvre
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While there is a substantial body of evidence indicat-
ing that the surgery-associated tissue trauma and wound
healing can promote growth, angiogenesis and meta-
static ability of cancers [33], data on the possible homeo-
static connection between primary tumour and its
metastases are lacking. Our finding that the time to sec-
ond surgery is influential on the risk level only for IBTR
and CBC patients and not for REC patients suggests that
tumour removal, which occurs in the former groups
only, plays a specific role on metastasis development.
This idea is in agreement with the recalled model of
breast cancer metastatic development [7] if one takes
into account that the manifestation of IBTR or CBC, i.e.
of a macroscopic breast tumour, is preceded by a num-
ber of months of subclinical disease. According to the
tumour homeostasis concept [7], during this time span,
the growing tumour exerts constraints on distant micro-
scopic foci, somehow mimicking the homeostatic pro-
cesses underlying the control of size in adult organs and
organisms [34, 35]. Although the molecular characteris-
tics of these mechanisms are largely unknown, recent re-
ports have provided initial interesting findings [36, 37],
which may have oncological important implications as
well [38].
In patients suffering IBTR or CBC, a number of meta-
static foci are related to the previous breast cancer, al-
though a few of them may be associated with the new
breast neoplastic lump. The emerging restrictive inter-
ference results into some freeze of the microscopic
metastases in the conditions existing when the new
homeostatic action is starting. Taking into account the
hazard rate dynamics for the DM related to the primary
breast cancer [7], such a freeze should have effects de-
pending on time to second surgery: the shorter this time,
the higher the underlying DM risk. Consequently, while
the DM dynamics after the IBTR or CBC removal main-
tains the usual time-related pattern, the corresponding
hazard rate level would depend on time to second sur-
gery. Following 2 to 3 years, the time to second surgery
loses its prognostic value, in keeping with the drop of
DM risk attributable to the primary breast cancer [7].
The finding that patients undergoing REC do not
present any effect from the time to second surgery, while
displaying the usual time-related pattern in the
post-reconstruction DM dynamics, suggests that the re-
constructive surgical manoeuvre, in the absence of any
breast tumour removal, may act on metastasis develop-
ment differently from IBRT and CBC surgical removal.
As a working hypothesis, it may be assumed that surgi-
cal manoeuvres prominently act on the microenviron-
ment of tumour foci turning it into conducive (e.g. by
activating angiogenesis) and thus sustaining growth [39].
This facilitating action would simply speed up the clin-
ical appearance of some metastases that would emerge
later according to their own dynamics. This hypothesis
is suggested by the comparison between the hazard rate
patterns for DM in REC patients and in the matched
paired control group (Fig. 6). This comparison suggests
Fig. 5 Distant metastasis dynamics following surgery for IBTR (t = 0 at IBTR) in patients with axillary node positive (left) or negative (right). The
analysis was performed for all patients and, moreover, by time from primary tumour removal to surgery for IBTR. While nodal status affects the
risk level, which is higher for node-positive patients, the time to surgery for IBTR is still influential on the first peak height if it is less than about 3
years. Y-axis reports hazard rates for DM, i.e. the conditional probability of manifesting DM during an interval of 6 months, given that the patient
is clinically DM free at the beginning of the interval. X-axis units are months between primary tumour removal and the second
surgical manoeuvre
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that the reconstruction is associated with a decrease of
the hazard rate for DM at the fourth year and a con-
comitant increase of the hazard rate at the second year.
The present findings are coherent with and integrate
the evidence coming from separate studies on IBTR and
REC, resorting to advanced time scale statistical model-
ling [16, 40]. The overall picture provided support to the
biological hypothesis, underlying the observed distant
metastasis dynamics following surgeries performed after
primary breast cancer surgical removal, according to
different tumour homeostasis-related and surgical
wound-related effects on metastasis development.
The analysed databases did not included data on
HER2, preventing investigations on triple-negative
patients. Moreover, we could not analyse the possible
role of anaesthetic management, which potentially
influences the long-term outcome most probably in
patients undergoing more extended surgery [41], due
to missing information about this factor.
Conclusions
In summary, the findings of the present analysis support
the concept that the impact of breast tumour surgical
removal (either primary or IBTR or CBC) on micro-
scopic metastases is twofold, inasmuch as two different
factors, i.e. tumour homeostasis interruption and surgi-
cal wound effects, are involved. The removal of a breast
tumour would result into the sudden elimination of
the restrains on metastatic foci, thus allowing metas-
tasis development, which, in turn, would be supported
by the forwarding action of the mechanisms triggered
by the surgical wounding. This surgery-related
phenomenon would underlie the behaviour of DMs in
the REC group, where no detectable tumour deposit
is removed. While associations of such latter
phenomenon with surgical-related inflammatory con-
ditions and different anaesthesia modalities are sug-
gested from a few clinical data [41–43], the biological
mechanisms underlying tumour homeostasis are
largely unknown. Investigations in this field are
urgently warranted.
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